¦ɠŖįȶ0ϾƙȬ̪ȶ
1 Ͷú0Ϸ˦˷̍(1)f]w\зP-MT΅ĵĪхZuprevoиɀͶúEȹĆǩî+B΅ú Zuprevo 1Ưǩ 23 ư.ɫƢ*K\ıĭŁзBRDи
0¥ϻʆˣͶ?4ydıĭŁˠзSRDи0ʆˣͶ+)Ưǩ 24 ư.̝ŉ+
Pme*K\ıĭŁˠзBRDи0¥ϻʆˣͶ+)δŠϷŲC#Ưǩ 27ưнȸ.1ɫƢ.) SRD 0¥ϻͶ?4рϙ·Ⱦʩ50ǲϑāǯΡ
C#з˴˪β˒ǟŖϥи

(2)

CPZEN-45Pz[J\(Caprazamycin)О0àϕɶɕPza0΢ƓÅ CPZEN-45
1K^E˓#ǣɏʆˣΛЩ.)ͶúǣĞǛ̮ɕͮ(H37Rv)08-@πťú͈Ǜ̮ɕͮ (XDR-TB) .Ə);ȹĆ*

B+E΋ì#ɀċħ˂1

C7*0ǳ̮ɕͶ+1˜-Bɥ˪Ϩ̨EϼƇB+*̮ɕͮ0̪͑Ŝ0ȢΌħǩEűB+EȬ@.#!0ŽÞǛΛЩ.)ˉŌ7*.˃.ļЛ+-B?-ɸǛ1Ρ:@C)-ȮưƷ.ǀ̴ɀċħ˂0Ϸ˦.ī#ù͟ƳΛЩE̴̳*

B@.͟ƳΛЩ0ƄȤ.ī)ƣɠ˪-ŦϮḚ̂ʊ0˺̏0#:0ɟΓEƄȤ*Bз̓ 2 ˑ˂ʒǛ˷̍ϥþͶċŹ˷̍ϥŉãŤ¼ɠ̝ŉŉ̏;ˑ˷̍ǭ̝ŉXlƢ̏ŦŹи
(3)2-OH-ABKHqϧ̡Åǳˑ˂λH|P\(Arbekacin : ABK)0΢ƓÅ0 2-OH-ABK 1
ABK ?A;͙ɸǛÂʣABK ǣĞǛͮ08-@ ABK ͈Ǜͮ.Ə);ȹ
Ć*B+E΋ì#ɀċħ˂EϬˡ̪ͮǣɏˡ.ƏBͶú+)Ϸ˦6

΅ϗX^k0øʣȼǌCBƣɠ˪ħǩʊ0Ϸ˦.ī)ĖȠ+-Bŧʻ˂0Ćˈ˪-ŦϮḚ̂ʊ0ɟΓEϚ:)BзþͶċŹ˷̍ϥ̓ 2 ˑ˂ʒǛ˷̍ϥи(4)kz}zfǳUЄǛͮʒǛE˽kz}zf C 0Ϸ˦.īǭãĦ˷̍ϥ-@4.ŉãŤ0˷̍ɩϹ+0àĩ˷̍Eͼ&)Bɀċħ˂1Ĕú*K^0
MRSA Þτǣɏj.)̓нϡǵͶ*ʆˣĆɌE˽+Ŧ-˃Ǔ*

BsXJ\+ĩ̔0ÖC#

Bɀċħ˂1ȥŷͶ+1˜-BŔλEɥ˪+)A!0ˑ˂˂ˋŹ˪˱¨Æ˓.')ŉã˷̍ɩϹ+àĩ˷̍E̴̳9)Ϛ:#@.|dTdúз}m`xLPs}pи+Ç˓
B+* in vitro *˱¡˪.ǄǳͮʒǛE˽+E΋$##:K^
0 MRSA 0ǣɏjE˓)Ç˓ˣʊ.BʆˣĆɌ0ɟΓEϚ:)B

7#ͼ)kz}zf0đħǩ΢ƓÅE˓)ɣϗʒǛ˱Ϲ˷̍˱¡Ǜ0ɩƴΐɊE:#з̓ 2 ˑ˂ʒǛ˷̍ϥĈ˂ȤΗþͶċŹ˷̍ϥŉã˷̍ɩϹʘŤŦŹи

2лͶúϷ˦.ī#Ŕ˼˷̍
2.1

ǳǣɏˡͶ

(1)

ǳͮͶ0Ȇ̩˷̍1

MRSA-VRE ΚỊ̀HqUX\l͈ǛͮΚỊ̀T^k]KΚỊ̀{XsTdwΚỊ̀ǳϩͮΚỊ̀̔0Ħ̉ΚỊ̀E˓ǳˑ˂λ0ΚÌEͼ&#з̓ 2 ˑ˂ʒǛ˷̍ϥи

2

ùưƷ.ǀ̴16S rRNA fa˒ˑHqUX\ḷǳˑ˂λ͈ǛͮEƓÝȢΌHqUX\ḷǳˑ˂λ0Ȇ̩Ę4ȢΌ΢ƓÅ0ħǩ+!
0ΚÌ˷̍Eͼ-&#з̓ 2 ˑ˂ʒǛ˷̍ϥþͶċŹ˷̍ϥŉ̏ŉЈĎˣ˷̍`dи3

MRSA/VISA .˃Ǔ

BǳͮʒǛE˽ċħ˂0ɣϗEʃƁ!0Æ˓ɩƴΐɊ0̮ɌE;+.Ƅ˓ċ.ī)ŉã¼ɠ+àĩ˷̍Eͼ-&)Bз̓ 2ˑ˂ʒǛ˷̍ϥîŶɣϗΐɊϥþͶċŹ˷̍ϥЗŧŕŦŹи4

ɞ˂ˠ.Ə)ϻЁĆɌE˽̪ͮ§ǩîöỊ̌зTCSиϼƇú\UmJ\El+#Ȇ̩˷̍Eͼ-T^k]Kƙͮ.ƏϡǵǛ0Ьċħ˂EȢ#.΋ì#Ĉ˂ƄЩ0̮Ɍ@°Ǎ0ƘϷ.')ɟΓ)B
з̓оˑ˂ʒǛ˷̍ϥƛƚŦŹϏ˝ŦŹи5Ȧɀ*ò:)îЍC# NDM-1 ˑ˒Ŧ͛ͮÏȹB NDM-1 EXl)
Bz^l0¿ȒɩɣΐɊEîЍ×*B˅ēĎ̆ŦŹ+àĩ*Ϛ:)BǑˑ˂œФʚJy0^TnU?Az^l¿ȒϼƇ˂λ0Ȇ̩Eͼ&)Bз̓ 2 ˑ˂ʒǛ˷̍ϥ˅ēĎ̆ŦŹи

10

6

ЂǛͮ.ȹĆ-ȢΌǳͮċħ˂0Ȇ̩EǑċ˷VPJy
?Aͼ&#з̓ 2 ˑ˂ʒǛ˷̍ϥþͶċŹ˷̍ϥǣɏ˷и

(2)ǳJxM[KJ^Ͷ0Ȇ̩˷̍JxM[KJ^0śɳEϼƇBċħ˂0^TnUEǑċ˷ċħ˂Jy@ͼ&#śɳϼƇ΋@C#ċħ˂.')!0ϼƇɩɣEΐɊ#7#ĩƁ#ċħ˂0΢ƓÅƘϷ?4KJ^śɳϼƇʒǛ0ΚÌEͼ&)BзþͶċŹ˷̍ϥ̓ 2 ˑ˂ʒǛ˷̍ϥ̓ 3 ˑ˂ʒǛ˷̍ϥи

(3)ǳ B ŏ͌ʷKJ^ú0Ȇ̩˷̍
B ŏ͌ʷKJ^0Wq·΅ɩɣEϼƇBċħ˂EȆ̩B#:.Hjq
KJ^|TdE˓#KJ^Wq·΅ΚỊ̀Eɣ̛#ɣ̛#Hg`J̣E˓)Ǒˑ˂œФʚĘ4ċħ˂Jy0^TnUEͼ&)BϼƇʒǛE˽ċħ˂.')1Æ˓ɩƴΐɊEϚ:)Bз̓ 2 ˑ˂ʒǛ˷̍ϥ̓ 3 ˑ˂ʒǛ˷̍ϥɈ¬ŦŹĎ̆Ź˷̍ǭи

2.2

ǳFú

(1)

ziHbϼƇúf}zf0΢ƓÅħǩ˷̍
C7*.ħǩ#f}zf΢ƓÅ0*̭ğǲ*Ǆǳ͚ˢʒǛE˽ċħ˂Eǎ#ˉŌziHb+ϼƇú0·ħÅ0̮ȲEÆǩ*BзʇʑȔǭĈ˂ȤΗȹɩħǩ˷̍ϥîŶɣϗΐɊϥи
(2)ɒФСХϡǵ˪̪͑ɸǛ˂λ0Ȇ̩˷̍ɒФСХ˄Ǥ0F̪͑.ϡǵ˪-̪͑ɱE΢ƓBċħ˂Eǎ#@.ɀċħ˂0Æ˓ɩƴΐɊEͼ!0̪͑ãɥ˪îŶEȬ@.#зʇʑȔǭЗŧŕŦŹŉã¼ɠи

(3)Hk\^E΢ƓBċħ˂0˷̍
FϹϘϢ¿ŶEɥ˪+#^TnU?Aǎ@C#ȢΌċħ˂0̏ÅɣϗEʃƁ#(ʇʑȔǭîŶɣϗΐɊϥŉã¼ɠ)(4)

ù̏͜F.ȹĆ-ċħ˂0Ȇ̩ǳù̏͜FʒǛE;' androprostamine 0΢ƓÅħǩEͼɣϗʒǛ˱ϹE
ΐɊ#7#ù̏͜F.Ͷú͈ǛE;#@ AR sHkEöǏBńŶ11

0Ȇ̩Eͼ&)BзʇʑȔǭĈ˂ȤΗȹɩħǩ˷̍ϥ)(5)

Fкϸλ˱¨Æ˓Eõ˓#ǳFú0Ȇ̩˷̍F̪͑+ϸλ̪͑.B˱¨Æ˓Eõ˓Ȣ#-Fʆˣ0#:0îŶɥ˪
0˷̍Eͼ++;.0˱¨Æ˓EöǏBÂîŶċħ˂0Ȇ̩˷̍E̴̳
)BC7*0ΐɊ@rK^RwUdtT0 GAPDH F̪͑
0śɳEǱöBʒǛEȹB+EȬ@.#!*GAPDH 0ϧñ@ĩʒǛE˦ȍB}zfl0þ΅Eͼ-&)B7#͐F̪͑+ϸλ̪͑0àœФ^TnỤ@˦΋#ȢΌċħ˂Jd|q.')1ǳ
FʒǛ0Æ˓ɩɣ0ΐɊEͼ-++;.Ȣ#-ʒǛ+)ǳwͮʒǛ.
');΢ƓÅ0Ϸ˦Eϕ)ɟΓ)Bз̓ 1 ˑ˂ʒǛ˷̍ϥʇʑȔǭĈ˂ȤΗȹɩħǩ˷̍ϥɈ¬Ͷ̆ŦŹи

(6)ɩ͒ǛǳÅ0Ϸ˦˷̍ǳFʒǛEȹBǳÅEÆ΅îŶɥ˪ǳFú+)Ϸ˦Eͼ&)BÆ
˓ɩɣ?4ϡǵö0ΐɊEͼ-++;.ukRċEͼ-&#з̓ 1 ˑ˂ʒǛ˷̍ϥʇʑȔǭŉã¼ɠɈČŦŹи(7)ǞǛ͚͘ˢ̭͚́ͨ͞Ǳö˂λĔЍE˯Ǿ# EGFRvIII ϼƇ˂0Ȇ̩˷̍
EGFRvIII EϜü˦ˉ#K^̵̪̿ͨ͑E˓)ρŗГËŷ˪śɳEǾɥ+BˤĖǛ EGFRvIII ϼƇ˂λ^TnUEͼÂîŶċħ˂Eǎ#ʒǛ˂λ0Æ˓ɩɣEΐɊB++;.΢ƓÅċ.?&)?AǄÿ-ǳFʒǛE˽ċħ˂0þ΅Eͼ-&)Bз̓ 1 ˑ˂ʒǛ˷̍ϥȹɩħǩ˷̍ϥи
(8)F˃˜˪Ϩ̨ϼƇú0Ȇ̩˷̍F˃˜˪-Ϩ̨.ƏBϼƇúEǑˑ˂œФʚ?4ċħ˂Jy?AȆ̩#зʇʑȔǭîŶɣϗΐɊϥɈ¬ŦŹĎ̆Ź˷̍ǭи

2.3

ĎͶĵ0Þ˘˪Ḛ̂E˯Ǿ#ħǩ(1)

ĎͶĵ?4ȹ˓ˑ˂ʒǛ˂λ0ΑŴ˪Ȟħǩʊ0Ϸ˦1)ǳ̮ɕͶÒ΄ċħ˂ CPZEN-45 0ΑŴ˪ȞħǩʊEϷ˦#зȹɩħǩ˷̍ϥи2)̪͑ɸǛE˽ʘʏ˒TJl leptolyngbyolide C 0ΑŴ˪ȞÞħǩEϞǩ̲Ə̏Åϧ̀EʃƁ#зȹɩħǩ˷̍ϥи

12

(2)

ŽÌ- NdCl3•6H2ONaOtBu EΑŴĖȠ+BƄ˓˪- anti ϡǵ˪ΑŴ˪ȞnkHlěǘE˓) TON >1600 E˦ˉBxħḳ̌Eɣ̛
ǳ COPD Ͷ AZD5423 0Ƅ˓˪ħǩʊE˺̏#зȹɩħǩ˷̍ϥи

(3)

H`knkE˰ȇɾɕ̉ùШÅE˓BЬЎƷěǘ0Ϸ˦.ǿ8Vf
50ΑŴ˪Ȟ Mannich ŏěǘEϞǩ#ˑǩ˂1ħǩċŹ˪.ȹ˓-ÚŹʒǛ α,α-2 ̀ȌHqϩ΢ƓÅ.šȌġ͒*(4)&#зȹɩħǩ˷̍ϥи

Hl0Mqk0ΑŴ˪˦ˑʊEǘ˓ƘϷα-rWŏHlEϠ˓Běụ̈́Eɣ̛#зȹɩħǩ˷̍ϥи

(5)Pϩ+H@0͗ɼ.?BΑŴ˪-Hlǆǩěǘ.ȹĆ-ȢΌ~K̨ΑŴЪɖE΋ìɆºȷϠċ.?AƲ̚-Ŕλ̓.Ə)Ƅ˓˪ˏŚΦĳŏHlħǩʊEȊÊB¦E˺Ρ#зȹɩħǩ˷̍ϥи

2.4

KJ^˟ǝ0˦ˡɩɣΐȬ0Ŕ˼˷̍?4!0ǘ˓(1)

OKJ^˷̍
ȮưƷ7*.ĩƁ#2'0OKJ^Ťɵ}zflEͶúEÅã.ĆɌ˪.ϛȐB#:0drug delivery system (DDS)+)Ϸ˦B#:.ΕŤɵ
}zfl0̪͑ǾīǛ.')ɟΓEͼ&#з̓3ˑ˂ʒǛ˷̍ϥи(2)JxM[KJ^˷̍JxM[KJ^18ɀ.î̙ċC#RNAWqEǽ'8ɀ0Wqн'0̟Ŷ.ĝAώ7CB¦1ǣɏǛ̟Ŷǆǩ.ǖИ*B+@Ȣ#-þͶdWgk+)8ɀ0RNAWq'0̟Ŷ.ĝAώ7CB0.ǖΊϧñ.')ΐɊEͼ&#з̓3ˑ˂ʒǛ˷̍ϥи
(3)

HIV ˷̍
HIV-1 ˒ˑB˵ϳ RNA (short transcriptцST)0ǝ͇Åã.BŷŌǡ̈́EȬ@.B+E˯˪. HIV−1 ЄǛ͇0ͻʚ0ǣɏ̪͑ã.B ST
ɟìʊ0Ϸ˦+!0ΐɊEϚ:ŉ̏ǣɏˡ˷̍ǭɈ¬ŦŹĎ̆Ź˷̍ǭϾƙˠЀ+0àĩ˷̍*͟ƳɟɑʊϷ˦E˯Ǿ#Ŕˮ˷̍Eͼ&#з̓ 3 ˑ˂ʒǛ˷̍ϥи

13

(4)B ŏ͌ʷKJ^˷̍
B ŏ͌ʷKJ^0Wq·΅EШĈBKJ^ńŶ<ƊńŶ0@Ȣ#-þͶɥ˪îŶEĩƁB+E˯˪+)Wq·΅.˃ċ#œФ̪͑ΚỊ̀Eɣ̛#ˉŌɣ̛#ΚỊ̀E˓#ċħ˂Jy?4Ǒˑ˂œФʚ0^TnUEϚ:KJ^Wq·΅0îŶŔˮ.ϐB#:0ċħ˂0ĝǎE˯Ǿ)B@.΋ì#ċħ˂.')1!0Æ˓ɩƴ.')ΐɊEϚ:)Bз̓ 3 ˑ˂ʒǛ˷̍ϥɈ¬ŦŹĎ̆Ź˷̍ǭи

2.5

OkxG]0ɣϗˑ˂Ź˪˷̍(1)OkxG]0ŲĈ1Atg1-Atg13-Atg17-Atg29-Atg31 ·ħÅзAtg1 ·ħÅиǷ&)BRma0ʒǛɀÅ*

B Atg1 .')ЬϖĖŶϸÿМǑϴ.?AÞϵ0ɣϗEȬ@.#@. Atg1 ͠τǽ'RmaʒǛ.?B
͠ƥϩċ.?AAtg1 0ɣϗšċB+EȬ@.#зîŶɣϗ˷̍ϥи
(2)

Atg8 1͓λ PE +̮ħ)͝ƖŌɤ-ńŶ+͝*˱¨Æ˓EǆǩBǪ¸ùĩƁ# Atg8 ̮ħfx1 Trp-X-X-Leu ɤϧñEǽ%'À4#ɣϗEĝB°ŃȢ#. Hfl1 +dtTλ.΋ì# Atg8 ̮ħϧñ1Þ˜-BϧñEǽ%̮ȲɣϗΐɊ0̮Ɍ{gT^ɣϗEĝ&) Atg8 .̮
ħB+E΋ì#зîŶɣϗ˷̍ϥи(3)

OkxG].ǖИ*Bɣϗɩ͒ǟŖ7&#-&#ńŶAtg2.')!0Nȿ̒lJ0̮Ȳċ.ǩĀ#@.˜ƫîȚʊ.?BΐɊ.
?&)òȼɣϗEʃƁB+.ǩĀC7*Ŗį0-ȢΌlJ*B+EȬ@.#зîŶɣϗ˷̍ϥи

2.6

ȩ͸z]LTkè͸Ţͬ-,0ȩ͸ˠĖ̢˄ͮ.ϹB˷̍

(1)ˑˋʒǛ˂λ0Ȇ̩ʪ+-Bè͸ŢͬEǕ+#ȩ͸ˠĖ̢˄ͮ0ȅĝîЍœФEͼ¶ά˒˂0ťɤċ0ɟΓEͼ&#Jy@0ʒǛ˂λ0ħǩО̻ÅħǩEͼ&#зʇʑȔǭи

14

2.7

ЎʆṶ̈̀́̕˟ǝʆˣͶЎʆṶ̈̀́̕˟ǝ.ƏBʆˣͶE˯Ǿ#Ŕˮ˷̍(1)̭́̕˟ǝ.àϕBˠǤ0'+)̭́̕ȇħϥ0͔ǂ

Bɀ˷̍*1̭́̕ȇħϥ0ρŗ+-BH`fX`zd0êЋʒǛEīBċħ˂EȆ̩B^TnUEͼ&)BɀưƷ;ǀ̴^TnUE̴̳Ǒˑ˂œФ˂@˯˪0ʒǛEȹBugky^нɔ.')
ʒǛΚÌĘ4ʒǛ˂λ0̠΅Eͼ&#з̓ 3 ˑ˂ʒǛ˷̍ϥɈ¬ŦŹĎ̆Ź
˷̍ǭи
(2)

ЎʆṶ̈̀́̕˟ǝ*B͕ЫǛ̕ͱ̽ˡ(SMA)0ȢʆˣʊϷ˦E˯Ǿ#ťȤΗàĩĎƩƓʆЩ0ƄȤ˷̍(ȦɀĎˣ˷̍Ϸ˦ɩɣЎʆǛƄ˓ċ˷̍¦ɠ).ė˗Ùͼ˷̍.)˅͠.Ϸ˦# SMA ĖńϢ¿Ŷ˒˂*

B SMN ͹

˨λ0ʦƁʊE˓)ʆЩZz0ʦƁEͼ&)BSMN ͹˨λ0ȢΌʦƁʊ.')1ŉã¼ɠ+àĩϷ˦EϷŲ#@.C@0˷̍EŔ.ȢΌ SMA ͶȆ̩^TnỤ0ɣ̛EϚ:)Bз̓ 3 ˑ˂ʒǛ˷̍ϥɈ¬ŰŶĎ̆ŦŹŉã¼ɠи
2.8

ɩ͒ǛOY̡О̻Åċħ˂ɩ͒ǛOY̡О̻Åċħ˂0Ƅ˓ċ.9#ɟΓ(1)Ϩ̨ЎîΐǛ0 trehalose О̻Åċħ˂ 6 ̉E΋ìHhrJˠEǕ+#̭́šǛ˟ǝʆˣͶ+)0ϠǛΚÌ<ΛͶ<Ħ̉ɄȠ+)0Ƅ˓ċ.ī#ɟΓEͼ&)B(̓ 1 ˑ˂ʒǛ˷̍ϥĈ˂ȤΗîŶɣϗΐɊϥ
̓ 2 ˑ˂ʒǛ˷̍ϥȹɩħǩ˷̍ϥ)

3лˑ˂θʪḚ̂ˑˋʒǛ˂λ0Jyċ3.1ˑ˂θʪ0Ḛ̂(1)ͮœФǶìʚ0ȊÊȖ̸ͮ+̪ͮEħD) 563 ɔ.')ʚÅœФ?4ňÅœФEͼ&#ɀœФʚ?4œФǶìʚ 3,410 ZzEǭã?4ǭŤ0àĩ˷̍Ù5ȊÊ#з̓ 1̓ 2̓ 3 ˑ˂ʒǛ˷̍ϥʇʑȔǭǦǘŦŹϏ˝ŦŹи(2)̠ƋλϮE˓#Ǒˑ˂œФ˂0 LC/MS jdΐɊ.')̠ƋλϮ-ÏǽȰϸjd|^EȵȢœФʚ0dΐɊEͼ&)BзîŶɣϗΐ
Ɋϥ̓ 2 ˑ˂ʒǛ˷̍ϥи

15

3.2

VPJy0ɣ̛

(1)

C7*ǅ˷̍ǭ*ĔЍĩƁC#ŧʻċħ˂?4İύċħ˂ȢΌħǩ˂E
Ǖ.JyċEͼ Ȣ#.605˂λE˧ϱ#з˴˪β˒ǟŖϥθʪ̘ˋƅи

(2)

ǭãŤ5ċħ˂0Ḛ̂E¸0ϕAͼ&#зĩ˂λ0·ȜȊÊĬ9и ǭã 40Zzз̞Åи394zkз15178Zzи ǭŤ 29Zzз̞Åи41zkз199Zzиз˴˪β˒ǟŖϥθʪ̘ˋƅи

(3)ċħ˂0İύǟŖEǼ̘ˋB#:jd|^bxkEƓÝå˧ϱÆɠEϚ:B+ĩȰ.ċŹɣϗȬ0;01ϠƂ NMRMS EʦƁB̔ǟŖ0̠ɑEƄȤ*

3.3

Bз˴˪β˒ǟŖϥθʪ̘ˋƅиͮJy0ɣ̛ȢΌîЍɔ0ĜЋ+)Ͳͳ?4H@0îЍ0ĝA̬8EϷŲ!C"C 883 ɔ204 ɔEĝǎ#îЍɔ0 16S rDNA ϥîϧñĝǎEͼ!C.?AœФɔ0ϡôEͼ&)B7#˃.Ͳͳ@0îЍɔ.1ťȜ0Ȣ̉ȢƙÒ΄Ĭ7CB+D&)Bŉã¼ɠ 1 ˿?AȖ̸ͮ 1,565 ɔPv 4,352 ɔEƓÝ#Ȗ̸ͮ.')1
16S rDNA ϥîϧñ0ĝǎEϚ:)A*. 70%¸0ɔ0ϧñEĝǎʠ8
Pv.')1ƓÝɔ0 3/4 ̈Ʒ.') 28S rDNA D2 ЙŒ0ϧñ0ȊÊEĞ)Bз̓ 2 ˑ˂ʒǛ˷̍ϥи

4лˏŚϹϘ
4.1

ˏŚļЛ.ƏBǑˑ˂0õ˓˦Аǭ̔*ЃȋC#TWО0ëˋ0ɟΓзîΐ+ȄɼëˋиEϚ:)Bɀ¦ɠ0ƣɠċ.ī)Ȅɼëˋˑ˂0ŽƁ˪ŦϮˑ˒EϞǩ#Ǒċ˷+Аÿ¾˿0¦ɠE¹±BˏŚϹϘ¾˿+1ǅΝǰͽ0õ˓ǰͽ̇φ.')ŭ̥ǩ̏Ļĵċ#ɀ¦ɠ.ϹϘ#˃Θ16)ǩ̏#зŉãŉŤ1ϥƍɑизʇʑȔǭŉã¼ɠи

16

4.2

`\K^kfK0ϻЁú0Ȇ̩ŉã*ȅЋ#ǷŶͮ Pisolithus orientalis ŶƄÅ@ȥ˴0 Cs ϡǵ˪Ȃρ*
B Norbadione A EʹϮĔЍɧ͓Ƿǽʊ.?A Cs ŃĜŃĜġ͒*

jƄЩEͼ Cs

B+E˽#Pisolithus orientalis 0ʚÅœФEͼx^XœФɆºɟΓ0̮Ɍ Norbadione A 1œō0PKʴƷEϠƷ.ʣ#œō*œФB+*ȷŦ 150µg/mL 0ˑ˒ǛE˽+Ȭ@.-&#7#œФɟΓз1LиEͼϕƫ0 Hagem œō* 57µg/mL 0ˑ˒Ǜǎ@C#з˴˪β˒ǟŖϥŉãŦŹи

5л˴˪β˒ƲŖ¦ɠ
5.1

˴˪β˒
ɀưƷ0˃ΘìНȜ 14 ºзŉã˃Θ 4 ºŉŤ˃Θ 10 ºи*

5.2

&#

ƲŖ¦ɠ
Ε0ŴÅ.)˷̍ǭ0ɢΊ˷̍ãƉ˷̍ǩɌE˦Ð#ɀưƷ0n^^?4ǅ˷̍ǭĝA@C#Ȣ͊˦Ϳ̔0Ξ̪1ô̦ưŖtxgk
~}]n^^6лŹͽȁ͢
6.1

ș͎?4˷̍ǾƓŉãŤ0ĕŞ˷̍ķŦŹЀˑĒɠ˷̍ˑ̔EĞÝCș͎?4˷̍ǾƓ
Eͼ&#

(1)

ș͎
ȧȼÅЩŹͅ0ƄȤз˷̍͋ƄōRHș͎?4ǭã΋Ź̔и˷̍ǭ΋ŹхǦǘ̈́řŦŹͶŹϥнưˑ Ǒċ˷(2016.5.10)
˷̍ǭ΋ŹхǦǘ̈́řŦŹˋƣŹϥǘ˓ċŹ̆ 3 ưˑ Ǒċ˷(2016.7.12)
˷̍ǭ΋ŹхВƛŦŹŹˑ?4șķ ʇʑȔǭ (2016.9.8)
͋ɠΔ̺хΆϭƦ̏ʛͥŹɓ 2 ưˑ ʇʑȔǭ (2016.10.26-27)˷̍ǭ΋ŹхH]HǣɏˡǷǅ͇0Ͷú͈Ǜͮ˷Ñзǣɏ˷@0ËКиз2016.11.16)
˷̍ǭ΋Źх\Hƣ̆ŦŹŦŹЀˑ ʇʑȔǭ(2017.2.20)(2)˷̍ķ0ĞÝC17˷̍ǾƓ0ɀưƷĞÝC˄ʈEΕ.Εз%ʘŤ@0ĞÝȜи

6.2
1 ĕŞ˷̍ķ  

12 (9)Ī ŦŹЀˑ   2Ī ÑŞ˷̍ķ  

2 (2)

Ī

 Ēɠ˷̍ˑ  6Ī JSPS ˃ô˷̍ķ

1 (3)

Ī

˷̍ǭΫ̈́
͹˨λ˱¨Æ˓ PPI EϼƇBċħ˂Ȇ̩+˂ˋċŹ˪-ϼƇÆ˓ΐɊʑɀ ʗƯșȃзɈ¬ŦŹŦŹЀƣẒ́˷̍̆Ɉ¬ŦŹþͶɩɣ DDI ɩɣâĉиϵ϶˶ ȴĂșзɈ¬ŦŹŦŹЀƣẒ́˷̍̆Ɉ¬ŦŹþͶɩɣ DDI ɩɣâĉиȣ Ǒċ˷ (2016.4.12)2̝ŉ˃ΘÏίϠɖǛ(Patent Subject Matter Eligibility).')Ǒˑ˂ Ϣ¿Ŷ

̔1˃Θ.-@-жчƾ˔ ʗǭϵзƚ0ǮħĩŉЈ˃Θ¦ĉǭиȣ Ǒċ˷ (2016.4.14)3

dtTλϸ˱¨Æ˓Eɥ˪+# in silico þͶǮʊ0Ϸ˦+Ƅς˔ʇ БșȃзɈ¬ˋ̆ŦŹͶŹϥ ˑċŹиȣ Ǒċ˷ (2016.5.11)

4ŧʻ˂^TnU0ȷϏ0ΜЛ+ˑħǩϢ¿ŶE˓#ȷȢ0ŧʻċħ˂ˑ˒ǰͽϷ˦Ȣƈ ˖Uzϵз˒ɠǰͽ̷ħ˷̍ǭ þͶŔˮ˷̍ϥ϶ ȷÙ̒sJOǰͽȆɾUzиȣ Ǒċ˷ (2016.5.16)

5

PJX0ǣɏ

jE˓#ȢΌǳˑ˂λJb\0˦΋Ϲɼ ĳșȃзƨ¬ŦŹĎ˳ͮ˷̍`dиȣ Ǒċ˷ (2016.7.7)
6

Development of natural products-based chemical tools useful for plant cellbiologyЬƛ ʏϊΫƩзɈČŦŹˋŹϥ ȹɩċŹΫƸиȣ Ǒċ˷ (2016.7.28)

7u^k H2A 0ϩċEɥ˪+#þͶ0Ȋɗ
½ͷ țșȃзϵƝŦŹĎŹϥ ˑċŹиȣ Ǒċ˷ (2016.8.26)

8ȢΌdHg`J.?BȢ#- Wnt ϼƇú0^TnUĠơ ʏșȃзɈ¬ŦŹĎ̆Ź˷̍ǭ ͟ƳWq͚ˢŹîϭи18ȣ Ǒċ˷ (2016.09.02)
9Primary sequence determination of a blood group B-specific lectin purified
from Streptomyces sp. 27S5 uncovered new insight into its mechanism ofexpression and unique structural features.
Ph.D., Yoko YamaguchiзBeckman Research Institute of City of Hopeиȣ Ǒċ˷ (2016.09.23)

10 ϪϨŧʻ˂Eʒ˓#þͶ˷̍щĎͶlþì0Jk+°Ǎ0ƘϷщɽª ʗ§ǭϵзŦбͶĵƣɠ ŧʻ˂xiIH˷̍ǭиȣ Ǒċ˷ (2016.09.26)
11 Design of Modular Chiral Ionic Catalysts for Asymmetric Reactions"Ŧɉ ­±˃»éșȃ (ĪĠƗŦŹƣŹϥ ĪĠƗŦŹ ITbM)
ȣ Ǒċ˷ (2016.09.30)
12 ˠĖǛϨɶP]eUyd0Ạ̊˪'̶́˪Ϣ¿Ŷ̬ȌÅXT\
E˓#ǳ˳ͮͶ0Ϸ˦˴ͦĕʆéșȃзĐͳŦŹ ˳ͮĎŹ˷̍`dи
13 Nazarov and Nazarov-Type Cyclizations
Prof. Marcus A. Tius (Department of Chemistry, University of Hawaii at
Manoa)ȣ Ǒċ˷ (2016.11.4)
14 ͓λ¶άϹϘϨ̨ Acetyl-CoA carboxylase (ACC)˦ˉɩ͒ΐɊ͍ʩϻɬ50ǘ˓ɂ дʐșȃзВƛŦŹ U̆Źǰͽ˷̍ǭиȣ Ǒċ˷ (2016.11.7)
15 Ϣ¿ŶȕšWq̹ЋE˓#jK^0Æ΅+uk˟ǝ50ǘ˓Ή ęŶĂșзɈ¬ŦŹĎ̆Ź˷̍ǭ Ϣ¿ŶΐɊȤΗиȣ Ǒċ˷ (2016.12.7)
16 Ƅ˓ċ<ɩ͒ΐȬEǗī#ˑ˂ʒǛŧʻ˂0Ƅς˪ħǩ˷̍ЎʋƼ̀ șȃзǒƜŦŹŦŹЀ ĎɰͶŹ˷̍ϥиȣ Ǒċ˷ (2017.1.13)
17 ŧʻ˂þͶ˷̍.)̄<&)#+ͷʁ ȯǇþͶXjIpdзŉ̏˷̍Ϸ˦ʊ®ȦɀĎˣ˷̍Ϸ˦ɩɣ þͶȔȎǫ˚ϥ ɈȦɀ̱Ǽϥиȣ Ǒċ˷ (2017.1.30)
18 ͓λˑ˂Ź50΢͓λťɤǛ0ǆǩɩɣ+ˑ˂Ź˪ǡ̈́ʞɼ ŸЉ˃»șȃзɈ¬ŦŹŦŹЀ ĎẒ́˷̍̆ŉ̏ŉЈĎˣ˷̍`d19ˋ¦ ͓λ\UmUz]LTkϵиȣ Ǒċ˷ (2017.2.17)
7л˷̍Ăǩ
ßˬʊ®+)¸0ĂǩEͼ&#

3,000 ĐäǦǨ̈́řŦŹˋƣŹϥǘ˓ċŹ̆Ǒˑ˂ˑ˒˂0̆Ź˪˷̍

100 Đä

ßˬβŅʊ®ȦɀǣɏˡĎͶĵē¾
The Journal of Antibiotics ðͼȎĂ8лɘʳʵũΕǚЦ0õ˓ÍϚõ˓ÍϚ0#:Ε0ÆɠEͼ&#Ƙ˽˂0АŶċ

JHKkšȵ

Ƙ˽zk0nHƘ˽˂0ǻØ

Ťɇ͇0΋Źɗã

9лΊɩŁ0È˓˄ʈ(1)ɕ˻ɻàа (NMR) ^}Tk0ʦƁǑˑ˂ċŹ˷̍ǭ.ῊC)BƯǩ 28 ưƓÝ0ȦɀАŶ΅ ECZ600R ɕ˻ɻàа΂̀0ɀưƷ0ʦƁȜ12,359 º*&#yP˿΅ AVANCE III 500 ŏ NMR ΂̀зƯǩ 23 ư 11 ȸ.ƓÝи0ɀưƷ
0ʦƁȜ12, 019 º*&#yP˿΅ AVANCE III HD 400 ŏзƯǩ24 ư 10 ȸƓÝи0ɀưƷ0ʦƁȜ120,577 º*&#ʇʑȔǭ.ῊC)BƯǩ 22 ưƓÝ0ȦɀАŶ΅ ECS400 ɕ˻ɻàа΂̀
0ʦƁȜ1322 º*
(2)

&#

ʚÅTkUxI/λϮîɊ^}Tk (LC/MS/MS) 0ʦƁǑˑ˂ċŹ˷̍ǭ.ῊC)BƯǩ 19 ư 7 ȸƓÝ0Z

xIg\Z

JMiIxIgT˿΅ LTQ Orbitrap λϮîɊΒ0ɀưƷ0ʦƁȜ1ÂîŶ 3,464 ºziOT^ 517 º*ȦĨȔǭ.ῊC)BZ

&#

xIg\ZJMiIxIgT˿΅ʚÅTkUxIмλϮîɊ΂̀ (Accela/LTQ XL)зƯǩ 19 ư 9 ȸƓÝи0ɀ
ưƷ0ʦƁȜ12,776 º*

&#

20

(3)

λϮîɊ^}Tk (MS) 0ʦƁǑˑ˂ċŹ˷̍ǭ.ῊC)BƯǩ 14 ưƷƓÝ0ȦɀАŶ΅ T100LC λϮîɊ΂̀0ɀưƷ0ʦƁȜ1 10,600 º*&#Ǒˑ˂ċŹ˷̍ǭ.Ưǩ 25 ư 9 ȸƓÝ0Ɯʑ΅Æǭ΅ AXIMA TOF2 λϮîɊ
΂̀0ɀưƷ0ʦƁȜ11,154 º*
(4)

&#

ξɑŏАŶМǑϴ0ȓǊǑˑ˂ċŹ˷̍ǭ.ῊC)BȦ̏ SU1510 ŏE˓)Ȗ̸ͮ̔ 25 Ń0ȓǊEͼ&#ɩə1ЗΦ.ϛφC)B

(5)ϔϜŏАŶМǑϴ0ȓǊǑˑ˂ċŹ˷̍ǭ.ῊC)B.ῊC)BȦ̏ H-7100 ŏзƯǩ 2 ưƷȦɀ͠φυȁ͢¾΄Ăϯи0ȓǊ1ͼD-&#ɩə1ЗΦ.ϛφC)
B

(6)ŦŏǑˑ˂œФ΂̀Ǒˑ˂ċŹ˷̍ǭ.ῊC)BῊC)B(ɔ)ͯsJOM]˿΅
MSJ-U3 30L ŏ?4 MPF-U3 200L ŏ]xGdзƯǩ 4 ưƷȦɀ͠φυȁ͢¾΄Ăϯи1ЗΦ.̋Ĉ)BɀưƷ.ϛφC#ŃȜ1
MSJ-U3 30L ŏ 34 ŃMPF-U3200L ŏ 20 Ń*

(7)

B

˰Τŏ|dPKdзkgT^ 9600 tgPlиʇʑȔǭ.ῊC)B©ě˔+ĩɤ.Ưǩ 6 ưƷȦɀ͠φυȁ͢¾΄Ăϯ*μÝ#kgT^ 9600M-˰Τŏ|dPKdзtgPl˿и1È˓C)@ĈÆͥ0#:ƽɛ¥Ɓ*

(8)

B

ʚÅ\f\PKdзTri-Carb2800TRtRMиʇʑȔǭ.ῊC)BʚÅ\f\PKd LSC-6100зHP˿и1ЗΦ.̋Õ)A13Ń290Zz0ʦƁEͼ&#(9)ĖŶĭÚ΂̀
Ưǩ 21 ư 3 ȸ.Ǒˑ˂ċŹ˷̍ǭзɀǭи.Ὴʘ˒ʀȏˑ˂0ëˋƣ̈*˦ˑBƽɼ.Ĭ7CBϬϯƙз˃.PlKи0ʦƁEͼ&)B

(10)ш̸ɣϗΐɊ΂̀зQT VariMax with RAPIDиƯǩ 23 ư 7 ȸǑˑ˂ċŹ˷̍ǭзɀǭи.ῊdtTλ̮Ȳ0RT21

da\?4ŃǴjdĜЋÂîŶċħ˂0ŃǴjdĜЋ.õ˓)BɀưƷ. 7 ̉О0dtTλ̮Ȳ0RTda\.õ˓!C@1ȖƑÚȤΗEõ˓B+*ɣϗʃƁ.ǩĀ#7#ÂîŶċħ˂.
')185 ̉О0̮Ȳ.')ŃǴjdĜЋ?4ɣϗʃƁ.ǩĀ#(11)

mqgdîʍ\^iзTTP LabTech mosquitoиƯǩ 23 ư 6 ȸǑˑ˂ċŹ˷̍ǭзɀǭи.ῊdtTλ?4ÂîŶċħ˂0̮ȲċɆº^TnU.õ˓)BɀưƷ.̥ 20 Ɇº0̮ȲċɆºɟΓ.È˓CdtTλ?4dtTλ-ċħ˂·ħÅ.Ϲ)
20 ̉О0̮ȲɊì.ǩĀ#(12)

In vivo J]U\^iOt^ OV110
Ưǩ 19 ư 11 ȸʇʑȔǭ.ῊͺÚdtTλ GFP EŽƁƓÝ#ukF̪͑ɔEol

B1^RglK^0˫?4ĩǭ.̇ɞ#̣E˓

)^TnU*ugk#ċħ˂0öˤʒǛEΚÌ)B
(13)

ʚÅTkUxI/λϮîɊ^}Tk (LC/MS/MS) 0ʦƁʇʑȔǭ.Ưǩ 24 ư 12 ȸƓÝ0Z

xIg\ZJMiIxIgT˿΅

Q Exactive λϮîɊΒ0ɀưƷ0ʦƁȜ1 4,208 º*&#

10лǑˑ˂ċŹ˷̍̔.ϹBŉЈ«ʓ10.1

ŉЈŹ¾-,50ìƪ зΞ̪1ô̦.ʝ´#иŉЈŹ¾-,.ìƪ˷̍ǩɌ0˦Ϳ?4˷̍Ϙ̯ǟŖ«Ȍ-,Eͼ&#

10.2

ʘŤ?A0ɇΖ͇

1

Hua Bai
Chairman of the Board, Zhejiang Hisun Pharmaceutical Co., Ltd.
ȣ Ǒċ˷ (2016.05.17)

2

Ph.D., Tianmin Zhu
Chief Scientific Officer, Zhejiang Hisun Pharmaceutical Co., Ltd.
ȣ Ǒċ˷ (2016.05.17)

3

Linghui Zheng
Director, Fermentation Development, Zhejiang Hisun Pharmaceutical Co.,Ltd.
ȣ Ǒċ˷ (2016.05.17)

22

4

Steven Eaton
Business Development APAC, MSD Animal Healthȣ Ǒċ˷ (2016.6.3)

5

Ph.D.,Juergen Lutz
Principal Scientist, Chemistry, MSD Animal Healthȣ Ǒċ˷ (2016.6.3)

6

Ph.D.,Yoko Fujita-YamaguchiзBeckman Research Institute of City of Hopeиȣ Ǒċ˷ (2016.09.23)

7

Ph.D., Lars Gredsted
Innovations, Wellcome Trustȣ Ǒċ˷ (2016.10.21)

8

Prof. Marcus A. Tius
Department of Chemistry, University of Hawaii at Manoaȣ Ǒċ˷ (2016.11.04)

9

Ph.D., Gerhard RothSenior Corporate Advisor, Huvepharma EOODȣ Ǒċ˷ (2016.12.1)

11лƏŤ˪-˷̍˦Ϳ (ΩȝŹ¾˦ͿȢ͊ŖϝĞἱ0Ξ̪1ô̦.ʝ´#)Ź¾ЌΠ-,0˦ͿΩȝ

40 Ŗ



ǹǌΫʮ

23 º



Ź¾˦Ϳ

78 º



˃ΘìН ŉã˃Θ6º˃ΘìН ŉŤ˃Θ

2º



Ğι

3º

23

ô̦

зниŹ¾ЌΠ-,0˦ͿΩȝ1

Small differences make a big impact: Structural insights into the differentialfunction of the 2 Atg8 homologs in C. elegans.
F. Wu, P. Wang, Y. Shen, N. N. Noda and H. Zhang.
Autophagy 12, 606-607, 20162Synthesis of androprostamine A and resormycin.
H. Abe, Y. Yamazaki, C. Sakashita, I. Momose, T. Watanabe, M. Shibasaki.
Chem. Pharm. Bull., 64, 982-987, 20163

Direct catalytic asymmetric Mannich-type reaction of alkylamides.
F. Arteaga, Z. Liu, L. Brewitz, J. Chen, B. Sun, N. Kumagai, M. Shibasaki.
Org. Lett., 18, 2391-2394, 2016

4Catalytic asymmetric synthesis of CPZEN-45.
T. Takeuchi, H. Abe, T. Watanabe, M. Shibasaki.
Tetrahedron Lett., 57, 2901-2904, 2016

5

Anti-cancer effects of green tea by either anti- or pro-oxidative mechanisms.
S. Hayakawa, K. Saito, N. Miyoshi, T. Ohishi, Y. Oishi, M. Miyoshi,
Y. Nakamura
Asian Pac J Cancer Prev., 17, 1649-1654, 20166Ǒˑ˂˕ɇȢΌŧʻ˂Ȇ̩.B MS 0ǋý
ʳ̐
J. Mass Spectrom. Soc. Jpn., 64, 2016

7

Structural basis for receptor-mediated selective autophagy of aminopeptidase
I aggregates.
A. Yamasaki, Y. Watanabe, W. Adachi, K. Suzuki, K. Matoba, H. Kirisako, H.
Kumeta, H. Nakatogawa, Y. Ohsumi, F. Inagaki, N. N. Noda
Cell Rep., 16, 19-27, 2016

8

9

10

A career in catalysis: Masakatsu Shibasaki
N. Kumagai, M. Kanai, H. Sasai
ACS Catal., 6, 4699-4709, 2016
Biological activities of unique isoflavones prepared from Apios Americana
Medik.
H. Kaneta, M. Koda, S. Saito, M. Imoto, M. Kawada, Y. Yamazaki, I. Momose,K. Shindo.
Biosci Biotechnol Biochem., 80, 774-778, 2016
Small molecules modulating tumor-stromal cell interactions: new candidates
for anti-tumor drugs.

24

11

12

M. Kawada
J Antibiot., 69, 411-414, 2016
An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses
infiltration of neutrophils and monocytes into inflamed dorsal air pouches.
M. Sue, N. Higashi, H. Shida, Y. Kogane, Y. Nishimura, H. Adachi,
E. Kolaczkowska, M. Kepka, M. Nakajima, T. Irimura
Int. immunopharmacology., 35, 15-21, 2016
Nucleophilic and electrophilic activation of non-heteroaromatic amides inatom economical asymmetric catalysis.
N. Kumagai, M. Shibasaki
Chem. Eur. J., 22, 15192-15200, 201613

The intrinsically disordered protein Atg13 mediates supramolecular assemblyof autophagy initiation complexes.
H. Yamamoto, Y. Fujioka, S. W. Suzuki, D. Noshiro, H. Suzuki, C. Kondo
Kakuta, Y. Kimura, H. Hirano, T. Ando, N. N. Noda, Y. Ohsumi.
Dev. Cell., 38, 86-99, 201614

SF-1 deficiency causes lipid accumulation in Leydig cells via suppression ofSTAR and CYP11A1.
M. Hatano, T. Migita, T. Ohishi, Y. Shima, Y. Ogawa, K-l. Morohashi, Y.
Hasegawa, F. Shibasaki
Endocrine 54, 484-496, 201615Catalytic asymmetric synthesis of the C1-C15 segment of spirastrellolide A
Y. Sahara, J. Cui, M. Furutachi, J. Chen, T. Watanabe, M. Shibasaki
Synthesis., 49, 69-75, 201716Influenza a virus hemagglutinin is required for the assembly of viralcomponents including bundled vRNPs at the lipid raft
N. Takizawa, F. Momose, Y. Morikawa, A. Nomoto
Viruses., 8, 249, 201617

Pyramidalization/twisting of the amide functionality via remote stericcongestion triggered by metal coordination.
S. Adachi, N. Kumagai, M. Shibasaki.
Chem. Sci., 8, 85-90, 201718Imaging flow cytometry analysis to identify differences of survival motor
neuron protein expression in patients with spinal muscular atrophy
R. Arakawa, M. Arakawa, K. Kaneko, N. Otsuki, R. Aoki, K. Saito
Pediatr. Neurol., 61, 70-75, 201619

Stability and bioavailability of lentztrehaloses A, B, and C as replacements for
Trehalose
S. Wada, R. Sawa, S. Ohba, C. Hayashi, M. Umekita, Y. Shibuya, K. Iijima,25

F. Iwanami, M. Igarashi
J. Agric. Food Chem., 64, 7121-7126, 201620Enantioselective synthesis of α,α-disubstituted α-amino acids via direct
catalytic asymmetric addition of acetonitrile to α-iminoesters.
S. Lin, N. Kumagai, M. Shibasaki
Org. Biomol. Chem., 14, 9725-9730, 201621

Anti-inflammatory action of green tea.
T. Ohishi, S. Goto, P. Monira, M. Isemura, Y. Nakamura.
Anti-Inflammatory & Anti-Allergy Agents in Med. Chem., 15, 74-90, 201622Structural biology of the core autophagy machinery.
H. Suzuki, T. Osawa, Y. Fujioka, N. N. Noda
Curr. Opin. Struct. Biol., 43, 10-17, 201623Strategic immobilization of molecular catalysts onto carbon nanotubes via
noncovalent interaction for catalytic organic transformations.
N. Kumagai, M. Shibasaki
Isr. J. Chem. 57, 270-278, 201624

Uique physicochemical and catalytic properties dictated by the B3NO2 ringsystem
H. Noda, M. Furutachi, Y. Asada, M. Shibasaki, N. KumagaiNat. Chem., 2017, doi: 10.1038/nchem.2708

25

Catalytic asymmetric synthesis of 2,3,3,3,-tetrafluoro-2-methyl-1-arylpropan
1- amines as useful building blocks for SAR-studies.
L. Brewitz, N. Kumagai, M. Shibasaki.
J. Fluor. Chem., 194, 1-7, 201726Epithelial-mesenchymal transition promotes SOX2 and NANOG expression inbladder cancer
T. Migita, A. Ueda, T. Ohishi, M. Hatano, H. Seimiya, S. Horiguchi, F. Koga,
F. Shibasaki
Laboratory Investigation, 2017, in press

27

Structural biology of the Cvt pathway
A. Yamasaki and N. N. Noda
J. Mol. Biol., 429, 531-542, 201728A novel monoclonal antibody targeting coxsackie virus and adenovirus
receptor inhibits tumor growth in vivo
M. Kawada, H. Inoue, M. Kajikawa, M. Sugiura, S. Sakamoto, S. Urano, C.
Karasawa, I. Usami, M. Futakuchi, T. Masuda

26

Sci. Rep. 2017 7:40400 doi: 10.1038/srep40400
29

Direct catalytic asymmetric aldol reaction of α-alkylamides.
Z. Liu, T. Takeuch, R. Pluta, F. Arteaga, N. Kumagai, M. Shibasaki
Org. Lett., 19, 710-713, 201730

Reversible stereoselective folding/unfolding fueledby the interplay ofphotoisomerism and hydrogen bonding.
C. R. Opie, N. Kumagai, M. Shibasaki
Angew. Chem. Int. Ed., 56, 3349-3353, 201731Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton
rearrangement and cancer cell invasion.
T. Ohishi, H. Yoshida, M. Katori, T. Migita, Y. Muramatsu, M. Miyake, Y.
Ishikawa, A. Saiura, SI. Iemura, T. Natsume, H. Seimiya
Cancer Res. 2017, in press doi: 10.1158/0008-5472.CAN-16-1846.

32

Catalytic asymmetric synthesis of CF3-substituted tertiary propargylic
alcohols via direct aldol reaction of α-N3 amide.
H. Noda, F. Amemiya, K. Weidner, N. Kumagai, and M. Shibasaki
Chem. Sci. 2017 in press

33

Vibrio japonicus sp. Nov., a novel member of the Nereis clade in the genus
Vibrio isolated from the coast of Japan.
H. Doi, I. Osawa, H. Adachi, M. Kawada
PLoS ONE. 12, e0172164, 201734Generation of a genetically stable high-fidelity influenza vaccine strain.
T. Naito, K. Mori, H. Ushirogawa, N. Takizawa, E. Nobusawa, T. Odagiri,
M. Tashiro, R. L. Ohniwa, K. Nagata, and M. Saito
J Virol., 91, e01073-16, 201735Asymmetric flow catalysis: mix-and-go solid-phase Nd/Na catalyst forexpeditious enantioselective access to a key intermediate of AZD7594
A. Nonoyama, N. Kumagai and M. Shibasaki
Tetrahedron, 73, 1517-1521, 201736Structure and antibacterial activities of new cyclic peptide antibiotics,
pargamicins B, C and D, from Amycolatopsis sp. ML1-hF4
H. Hashizume, R. Sawa, K. Yamashita, Y. Nishimura, M. Igarashi.
J Antibiot., 2017, Accepted, doi: 10.1038/ja.2017.34

37

Acremopeptin, a new peptaibol from Acremonium sp. PF1450.
M. Iijima, M. Amemiya, R. Sawa, Y. Kubota, T. Kunisada, I. Momose,
M. Kawada, M. Shibasaki

27

J Antibiot., 2017, doi: 10.1038/ja.2017.15.
38

Tyropeptins, proteasome inhibitors produced by Kitasatospora sp.
MK993-dF2.
I. Momose, T. Watanabe
J Antibiot., 2017, doi: 10.1038/ja.2017.9.

39

Efficient genome replication of hepatitis B virus using adenovirus vector: acompact pregenomic RNA-expression unit.
M. Suzuki, S. Kondo, M. Yamasaki, N. Matsuda, A. Nomoto, T. Suzuki, I.
Saito, Y. Kanegae
Sci. Rep., 7:41851, 2017, doi: 10.1038/srep41851

40

Cu/Pd Synergistic dual catalysis: asymmetric α-allylation of α-CF3 amide.
A. Saito, N. Kumagai and M. Shibasaki
Angew. Chem. Int. Ed. 2017 Accepted41Ͷú͈Ǜ+þͶ˷̍
HqUX\ḷǳˑ˂λEǕ+)
©ďƟЊ

Ьɨͥȯ

O|^T, 22, 7-12, 2017зоиʹȶ•̹Ћ•˭Ñ̔
1ŦɅȳĕŞq|ˑˋŹĎŹι,ȦɀͶŹ¾ĀąιĞιΕǚJdvɐеɭĊ Jdv
xG\H Vol. 52, No. 8 (2016)зпиǹǌΫʮ
1

Molecular Chirality Asia 2016
Recent Progress in Cooperative Asymmetric Catalysis
Masakatsu Shibasaki
2016 ư 4 ȸ 20 Ȧ (Knowledge Capital Congres Convention Center/ŦϺ)2

The 4th Sino-Japan Symposium on Autophagy
Structural basis of the Cvt pathway
Nobuo N. Noda
2016 ư 4 ȸ 23 Ȧ (Beijing /China)

3̓ 54 ŃuZJM^ sJOJdxLJ^
Ǒˑ˂ċŹ˷̍ǭ.Bŧʻ˂þͶ.')
©ďƟЊ

28

2016 ư 5 ȸ 31 ȦзÞˋϘv 9 І A ¾ήƅ/Ɉ¬и
4

Rare Earths 2016 in Sapporo Japan
Recent Progress in Coopetative Asymmetric Catalysis: Nd/Na Heterobimetallic
Catalyst
Masakatsu Shibasaki
2016 ư 6 ȸ 7 ȦзČʘϝŦŹŹͽ«ʓ¾ЦмɁƭи

5

̓ 58 Ńɣϗˑ˂ǘ˓˷̍¾
OkxG]0ɣϗˑ˂Ź˪˷̍ϭ˔Ƙˑ
2016 ư 6 ȸ 1 ȦзɈ¬ŦŹƚ¾ЦмɈ¬и

6

̓ 68 ŃȦɀ̪͑ˑ˂Ź¾Ŧ¾
OkxG]ŲĈ·ħÅ0ɣϗŔˮϭ˔Ƙˑ
2016 ư 6 ȸ 17 Ȧ з¬ϦiZ/¬ϦƦи

7

University of Bristol Ϋʮ¾
Exploration of Cooperative Asymmetric Catalysts Toward Efficient Synthesis ofTherapeutics
Naoya Kumagai2016 ư 7 ȸ 4 Ȧ (Bristol/UK)

8

University of Cambridge Ϋʮ¾
Exploration of Cooperative Asymmetric Catalysts Toward Efficient Synthesis ofTherapeutics
Naoya Kumagai2016 ư 7 ȸ 6 Ȧ (Cambridge/UK)

9

University of Oxford Ϋʮ¾
Exploration of Cooperative Asymmetric Catalysts Toward Efficient Synthesis ofTherapeutics
Naoya Kumagai2016 ư 7 ȸ 07 Ȧ (Oxford/UK)

10

̓ 25 ŃȦɀFφ̇Ź¾ŹͽЋ¾̷¾
Ɣ̪͑͏ˤ0͠ʻφ̇

j0Ϸ˦+!0ǘ˓ŎɀÑơ˔Źª΃ŦƺÎƱ˔ʎŶɚơˬ̤ɃʖЊ¯ʖϭĴŶɼΰşõżÄ͂½Ï͂ś˔ǔϭɀȬ˖ɐеɭĊ
2016 ư 7 ȸ 21 Ȧз̝ŶX|\`d/̝ŶƦи11International Conference on Stereochemistry
Catalytic asymmetric synthesis of biologically active natural products

29

Takumi Watanabe
2016 ư 8 ȸ 18 Ȧ (Sao Paulo/Brazil)
12

Symposium in Organic Chem. at Boston College
Recent Progress in Cooperative Asymmetric Catalysis
Masakatsu Shibasaki
2016 ư 9 ȸ 9 Ȧ (Boston College/Boston)13ȢŹͽЙŒ˷̍Źͽ˷̍ȔȎŔˮǆǩÙ̒jĈ˂ȔȎzgkxNͩǮȔȎǰͽΫͅ¾
C1ÈBжċħ˂JyVPsJO]0^^ơ˔Ź
2016 ư 9 ȸ 16 Ȧ (͵̆Ul~iʭ0ʨ/ϵϭ)14

Mc˷̍¾зHIGO zUȷÙ̒˷̍`mи
Structural insights into autophagy machineriesϭ˔Ƙˑ2016 ư 11 ȸ 2 Ȧ (ʼɀŦŹ˦ˑĎŹ˷̍ǭ/ʼɀ)15

2nd Kumamoto IRCMS International Symposium and 17th Kumamoto AIDS
SeminarShort HIV-1 transcripts in viral reservoirs and persistent immune activation.
Taketoshi Mizutani
2016 ư 11 ȸ 2 Ȧ (7;+˲ɺ«ʓЦtH/ ʼɀƦ)16

̓ 10 ŃOkxG]˷̍¾
Atg1 ·ħÅ0Ĉ˪ɣϗΐɊϭ˔Ƙˑ
2016 ư 11 ȸ 15 Ȧ (NASPA nOdn/Ȣʰ)17̓ 55 Ń NMR ΓΩ¾
NMR + X ̸̮ȲΐɊ0ēɠ@ϐBOkxG]0îŶɩɣϭ˔Ƙˑ̊ŐèǇ2016 ư 11 ȸ 18 Ȧ (ƲƜŉЈ¾ήŗ/ƲƜƦ)18

ĪĠƗŦŹ ITbM/IGER Chemistry Workshop 2016
HlE playground .#ěǘΗΒʼΰ˰Ķ
2016 ư 12 ȸ 19 Ȧ (ĪĠƗŦŹ ES ~/ĪĠƗ)19

19th International conference on Emerging Infectious Disease (EID) in the
Pacific Rim
Catalytic Asymmetric Synthesis of Potential Pharmaceuticals against
Infectious

30

Diseases
Masakatsu Shibasaki
2017 ư 02 ȸ 07 Ȧ (Seoul/Korea)
20ċǩĵƣɠē¾
HlE playground +#ΑŴěǘΗΒʼΰ˰Ķ2017 ư 2 ȸ 22 Ȧ (νŎ/Ɉ¬и21ċǩĵƣɠē¾
HlE playground +#ΑŴěǘΗΒʼΰ˰Ķ2017 ư 3 ȸ 8 Ȧ (ŦϺċŹǰͽ`d/ŦϺи

22

A3 ȦɀOkxG]ħĩ`m
Ȣū Atg8 ̮ħfx0ĩƁ+˱¨Æ˓Ŕˮ0ΐȬƚƝ̑ǒ, Li-Lin Du, ϭ˔Ƙˑз˦Ϳ͇и
2017 ư 3 ȸ 10 Ȧ ([`Tk̂Ɯ/̂Ɯ)
23

2016 ưƷϮŶvZJM^xL^dɣϗˑ˂Ź@ϐBOkxG]0îŶɩɣϭ˔Ƙˑ2017 ư 3 ȸ 14 Ȧ ('2ŉЈ¾ήŗ/ͫőизриŹ¾˦Ϳ
1

Molecular Chirality Asia 2016
Electrophilic Activation of α,β-Unsaturated Amide: Catalytic Asymmetric
Vinylogous Conjugate Addition of Unsaturated γ-Butyrolactone
Ming Zhang, Naoya Kumagai, Masakatsu Shibasaki
2016 ư 4 ȸ 20 Ȧ (Knowledge Capital Congrés Convention Center/ŦϺ)2

Molecular Chirality Asia 2016
Study on Catalytic Asymmetric Synthesis of Leucinostatin A
Hikaru Abe, Manabu Kawada, Takumi Watanabe, Masakatsu Shibasaki
2016 ư 4 ȸ 21 Ȧ (Knowledge Capital Congrés Convention Center/ŦϺ)3

Molecular Chirality Asia 2016
Catalytic Asymmetric Synthesis of the C1-C18 Segment of Scytophycin C
Jin Cui, Takumi Watanabe, Masakatsu Shibasaki
2016 ư 4 ȸ 21 Ȧ (Knowledge Capital Congrés Convention Center/ŦϺ)4

̓ 71 





α-H]l-7-H[JlHlE˓#kxOfVk50

31

eJTkŏΑŴ˪ȞHlěǘ0Ϸ˦ЏƆèɧϭ˔̃ÎKarin Weidnerʼΰ˰ĶɐƝɭĊ
2016 ư 5 ȸ 14 Ȧ (Ɉ¬όƣŦŹƔϯªRt^Ϋ̈́ɜ/Ɉ¬)5

̓ 71 





ŽÌŽƁ- Nd ŘE˓B Nd/Na ˜̉ 2 ɕϯƙΑŴ0ȢΌΦ΅ʊ0Ϸ˦ϭƚǉ®ɨɀĳɧгͷΣʼΰ˰ĶɐеɭĊ
2016 ư 5 ȸ 14 Ȧ (Ɉ¬όƣŦŹƔϯªRt^Ϋ̈́ɜ/Ɉ¬)6ɪ¶EǷȹɩċŹ\]KȢΌ·ɕ~K̨ΑŴE˓#˰ȇ˪Hlċěǘ0Ϸ˦ϭ˔̃ÎĠЦÐȻ˔ƼŶʼΰ˰ĶɐеɭĊ
2016 ư 5 ȸ 27 Ȧ (ϵªΕǚ~/Ɉ¬)7

̓ 18 ŃsJOiTq]Ź¾ʶǬãʘʘɼ?AîЍ# Vibrio ƙȾΕω̉0îОŹ˪ɟΓŋªſ͎Ŧʳ͎ŶÄͷǜ͂ŶŽϞćÚơ˔Ź
2016 ư 5 ȸ 28 Ȧ (ČʘϝŦŹɼ˒ŹϥíЦRt^/Čʘϝ)8

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾
Papyracillic acid ?4 penicillic acid .?BɒФСХϡǵ˪̪͑ɸǛ˩ʶĀŽϞćÚơ˔ŹɐеɭĊ
2016 ư 5 ȸ 31 Ȧ (ôƶŉЈX|\`d/Ŧî)9

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾
ȢΌǳFǳ CXADR ǳÅ 6G10A 0Æ˓ɩɣ0ΐɊơ˔Źª΃Ʊɚơˬ̤ɃʖЊ¯ŎɀÑʖϭĴŶżÄ͂½Ï͂2016 ư 5 ȸ 31 Ȧ (ôƶŉЈX|\`d/Ŧî)10

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾ÂîŶċħ˂ Ertredin ΢ƓÅ.?B EGFRvIII ˦ˉ̪͑0 3D-sphere ǆǩϼƇ+͚ˢǆǩǱö
ʥ͂ŊŶϭŎĐϫŽϞćÚŦƺÎª΃ƱȽɅȳĠɋͥǇʤύčϭɀȬ˖ơ˔ŹɐеɭĊʲΰɭģ2016 ư 5 ȸ 31 Ȧ (ôƶŉЈX|\`d/Ŧî)11

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾
ȢΌċħ˂ intervenolin .?Bϸλ̪͑0îʉńŶE±#͐F̪͑0śɳǱöĨ˔ʱɪϤª΃ƱŦƺÎЏƆȫ̃ś˔ǔϽϥÚʤύčơ˔ŹɐеɭĊ
2016 ư 5 ȸ 31 Ȧ (ôƶŉЈX|\`d/Ŧî)12

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾p53 Ëŷ˪̪͑śɳEϼƇBȢΌH^Rqċħ˂32̏˔Ŧϊ˩ʶĀЏƆȫ̃ʳ̐ʤύčÃĨκĮơ˔ŹɐеɭĊ
2016 ư 5 ȸ 31 Ȧ (ôƶŉЈX|\`d/Ŧî)13

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾Intervenolin ΢ƓÅ.?BwͮǱöĆɌ0ɟΓŦ˶ȳś˔ǔŦƺÎĖơȱŶżÄ͂½Ï͂˶е¯ƒɋĐͬ©ďƟЊϽϥÚʤύčЏƆȫ̃̊ƛÔenMČʯơ˔ŹɐеɭĊ
2016 ư 6 ȸ 1 Ȧ (ôƶŉЈX|\`d/Ŧî)14

̓ 109 Ńȹɩħǩ\]K
Cu/Pd sJdgTΑŴ.?B α-CF3 Hl0 α-ȞHċěǘгͷΣʼΰ˰ĶɐƝɭĊ
2016 ư 6 ȸ 8 Ȧ (Ɉ¬ƣɠŦŹ/Ɉ¬)15

Colorado Mycobacteria 2016 Conference
CPZEN-45; a promising drug candidate for treating extremely drug-resistanttuberculosis (XDR-TB): synthesis, activity, and mode of action
Yoshimasa Ishizaki, Kazushige Sasaki, Yoshiaki Takahashi, Masayuki Igarashi,
Toshiaki Miyake, Masaji Okada, Norio Doi, Patrick J. Brennan, Yuzuru
Akamatsu, Akio Nomoto, Masakatsu Shibasaki
2016 ư 6 ȸ 8-9 Ȧ (XlƢ/HP)

16

̓ 68 ŃȦɀ̪͑ˑ˂Ź¾Ŧ¾?4̓ннŃư¾ȦɀVPsJO]ŹħĩŦ¾
Identification of protozoan sorting receptor between the endoplasmic reticulum
and Golgi apparatus.
§ːʗΉЊЬɨͥĳɘʅʏ§ɐƝɭĊ

2016 ư 6 ȸ 15 Ȧ (¬ϦiZ/¬ϦƦ)17

̓ 43 Ń BMS XxG^ (BMS2016)
MALDI-TOF MS E˓#Ȗ̸ͮ0έôЬɨ΃Ŷ, ʋťϭĳɧ, ©ďƟЊ, ʳ̐, ɘʅʏ§, āͷĐȬ

2016 ư 7 ȸ 5 Ȧ (ʽʘ/Вƛ)18

̓ 43 Ń BMS XxG^ (BMS2016)
LC/MS 0wTǶì.BHeTkJOóƁ.')ʳ̐ТƜƧȫŶʋťϭĳɧ©ďƟЊɘʅʏ§

2016 ư 7 ȸ 5 Ȧ (ʽʘ/Вƛ)19

The 15th Belgian Organic Synthesis Symposium Antwerp
A Multiboton Catalyst for General Direct Amidation

33

Hidetoshi Noda, Makoto Furutachi, Yasuko Asada, Masakatsu Shibasaki, Naoya
Kumagai2016 ư 7 ȸ 11 Ȧ (Antwerp/Belgium)
20

International Symposium on Homogeneous Catalysis

ISHC 20

Direct Catalytic Asymmetric C–C Bond-Forming Reactions via Catalytic
Enolization of Amide
Toshifumi Takeuchi, Karin Weidner, Liang Yin, Lennart Brewitz, ZhongdongSun, Fernando A. Arteaga, Zijian Liu, Chen Jianyang, Bo Sun, Naoya Kumagai,
and Masakatsu Shibasaki
2016 ư 7 ȸ 14 Ȧ (¬ϦiZ/¬Ϧ)21

̓ 25 ŃȦɀFφ̇Ź¾ŹͽЋ¾̷¾
dRa̮ħ͹˨λ TANKS1BP1 .?BF̪͑ʙʱ͒0öǏŦ˶ȳĨ˔ĿЧĤ˔ȘȺɅɉ˕οŶŻ˳Ūвĝɭϝ˶ơЉȟʖ ȬũƈɅÎϤŢ˯ǔʞƆĽ
2016 ư 7 ȸ 21 Ȧ (̝ŶX|\`d/̝ŶƦ)22

̓ 27 ŃȢͶþ΅ΧΜ¾͛ã̪ͮ.<ȢΌǳwͮͶ0Ϸ˦Ŧ˶ȳơ˔Ź
2016 ư 8 ȸ 31 Ȧ (̖ʋƚ ʁǬƗ/̖ʋ)23

̓ 27 ŃŔ˼ȹɩċŹΓΩ¾
ϯƙϧÁ΢ο.?B̏ÅńŶ.οńBГƯДHl0Ȇ̩ρ̏ǥǁʼΰ˰ĶɐƝɭĊ
2016 ư 9 ȸ 2 Ȧ (ƲƜŉЈ¾ήŗ/ƲƜ˲)24ȢЙŒ˷̍Uz̠Ƌ˂λšȌ0#:0îŶ̎ϸċŹ

2016 \]KîŶϧñîŶ̎ϸEǡέ#ěǘΗΒʼΰ˰Ķ
2016 ư 9 ȸ 5 Ȧ (ϵƝŦŹ/ϵƝ˲)25

JASIS XxG^MALDI-TOF MS E˓#Ȗ̸ͮ0έôЬɨ΃Ŷʋťϭĳɧ©ďƟЊʳ̐ɘʅʏ§āͷĐȬ

2016 ư 9 ȸ 7 Ȧ (Ʈǃg`ŉЈ¾ήŗ/Ɉ¬)26

̓ 31 ŃȦɀȖ̸ͮŹ¾Ŧ¾
Lentzea ƙȖ̸ͮ˕ɇ lentztrehalose О0 trehalose ȕͥĵ+)0ŽƁǛΚÌĳ˔Îʳ̐ŦƺÎɋĐͬɘČ7<ʡΰÖŶТƜƧȫŶ©ďƟЊ
2016 ư 9 ȸ 9 Ȧ (Ɉ¬ŦŹόŹϥǁˑΫŕ/Ɉ¬)

34

27

̓ 31 ŃȦɀȖ̸ͮŹ¾Ŧ¾
ʛʘ˕ɇ Micromonospora ƙ0îОŹ˪˷̍ʋťϭ ĳɧЬɨ ΃Ŷʳ ̐©ďƟ Њāͷ ĐȬ

2016 ư 9 ȸ 9 Ȧ (Ɉ¬ŦŹόŹϥǁˑΫŕ/Ɉ¬)28

̓ 31 ŃȦɀȖ̸ͮŹ¾Ŧ¾
ƧƕȖ̸ͮ Amycolatopsis sp. ML1-hF4 ɔ0ˑ˒B˜ƫHqϩ cleonine ĬȹȢΌċħ˂ valgamicin C ?4ȢΌО̻Å0ɣϗ?4ˑ˂ʒǛɨʿ̃ɧƚĳ˳ТƜƧȫŶȽɅȳʡΰÖŶĳ˔Îʳ̐©ďƟЊ2016 ư 9 ȸ 9 Ȧ (Ɉ¬ŦŹόŹϥǁˑΫŕ/Ɉ¬)29

6th EuCheMS Chemistry Congress
Catalytic Asymmetric Formal Total Synthesis of Scytophycin C
Takumi Watanabe, Jin Cui, and Masakatsu Shibasaki
2016 ư 9 ȸ 12 Ȧ (Seville/Spain)30ȢŹͽЙŒ˷̍Źͽ˷̍ȔȎŔˮǆǩÙ̒jĈ˂ȔȎzgkxNͩǮȔȎǰͽΫͅ¾
ɒФСХ.BF˃˜˪¶άɩɣ0ΐɊƔϭƎųȝŎɀÑ˩ʶĀơ˔Ź
2016 ư 9 ȸ 16 Ȧ (͵̆Ul~iʭ0ʨ/ϵϭ)31ȢŹͽЙŒ˷̍Źͽ˷̍ȔȎŔˮǆǩÙ̒jĈ˂ȔȎzgkxNͩǮȔȎǰͽΫͅ¾olK^͏50ĩǭ̇ɞ.?BukƔ̪͑͏F0͠ʻφ̇

j0Ϸ˦+!0ǘ˓ŎɀÑª΃ƱŦƺÎƱ˔ʎŶɼΰşõżÄ͂½Ï͂ơ˔Ź
2016 ư 9 ȸ 16 Ȧ (͵̆Ul~iʭ0ʨ/ϵϭ)32

ãͷXxG^ˑĲ̆Ź.ЕĲE;#@ȷÙ̒ɣϗˑ˂ŹStructural mechanisms of receptor-mediated selective autophagy of aggregatedaminopeptidase I
Nobuo N. Noda, Akinori Yamasaki, Yasunori Watanabe, Wakana Adachi,
Kuninori Suzuki, Kazuaki Matoba, Hiromi Kirisako, Hiroyuki Kumeta, Hitoshi
Nakatogawa, Yoshinori Ohsumi, Fuyuhiko Inagaki
2016 ư 10 ȸ 5 Ȧ (\kaQkRUeZg/ɁƭƦ)33

ãͷXxG^ˑĲ̆Ź.ЕĲE;#@ȷÙ̒ɣϗˑ˂Ź
Activation mechanism of the autophagy-related E2 enzyme Atg3 by the
Atg12-Atg5 conjugate
Tatsuro Maruyama, Mariko Yokogawa, Han Xuerong, Nobuo N. Noda, Fuyuhiko

35

Inagaki2016 ư 10 ȸ 5 Ȧ (\kaQkRUeZg/ɁƭƦ)34

ãͷXxG^ˑĲ̆Ź.ЕĲE;#@ȷÙ̒ɣϗˑ˂ŹStructural basis of the pre-autophagosomal structure assembly mediated by an
intrinsically disordered protein Atg13
Yuko Fujioka, Hayashi Yamamoto, Sho W. Suzuki, Yoshinori Ohsumi, Nobuo N.
Noda
2016 ư 10 ȸ 6 Ȧ (\kaQkRUeZg/ɁƭƦ)35

ãͷXxG^ˑĲ̆Ź.ЕĲE;#@ȷÙ̒ɣϗˑ˂ŹStructure of Atg101 in complex with Atg13: Functional insights into mammalian
autophagy initiation
Hironori Suzuki, Takeshi Kaizuka, Noboru Mizushima, Nobuo N. Noda
2016 ư 10 ȸ 6 Ȧ (\kaQkRUeZg/ɁƭƦ)36

̓ 75 ŃȦɀˤŹ¾Źͽ̷¾
Ertredin, an inhibitor of sphere and tumor growth regulates OXPHOS andglycolysis in EGFRvIII-transformed cells
Sonoko Atsumi, Chisato Nosaka, Seiko Shimamoto, Hiroyuki Inoue, Shun-ichi.
Ohba, Tomoyuki Kimura, Takumi Watanabe, Manabu Kawada, Masakutsu
Shibasaki, Masabumi Shibuya
2016 ư 10 ȸ 6 Ȧ(t\xIXɦʕ/ɦʕ)37

̓ 75 ŃȦɀˤŹ¾Źͽ̷¾
p53-dependent growth suppression of cancer cells by coccoquinones
Daisuke Tatsuda, Manabu Kawada, Isao Momose.
2016 ư 10 ȸ 6 Ȧ(t\xIXɦʕ/ɦʕ)38

̓ 75 ŃȦɀˤŹ¾Źͽ̷¾
Papyracillic acid and penicillic acid show preferential cytotoxicity undernutrient-deprived conditions
Isao Momose, Hayamitsu Adachi, Manabu Kawada, Masakatsu Shibasaki.
2016 ư 10 ȸ 6 Ȧ(t\xIXɦʕ/ɦʕ)39

̓ 75 ŃȦɀˤŹ¾Źͽ̷¾
Mechanism of action of anti-CXADR 6G10A, a novel anti-tumor antibody
Manabu Kawada, Hiroyuki Inoue, Masunori Kajikawa, Masahito Sugiura,
Shuichi Sakamoto, Sakiko Urano, Ihomi Usami
2016 ư 10 ȸ 7 Ȧзt\xIXɦʕ/ɦʕи40

̓ 75 ŃȦɀˤŹ¾Źͽ̷¾Intervenolin, a novel compound, induces the suppression of gastric cancer cells by36

stromal cells via secreted factors
Junjiro Yoshida, Masahide Amemiya, Tohru Masuda, Hiroyuki Inoue, Shun-ichi
Ohba, Hikaru Abe, Takumi Watanabe, Manabu Kawada, Masakatsu Shibasaki
2016 ư 10 ȸ 8 Ȧ(t\xIXɦʕ/ɦʕ)41

̓ 75 ŃȦɀˤŹ¾Źͽ̷¾
Anti-Helicobacter pylori activity of a novel derivative of intervenolin
Tomokazu Ohishi, Toru Masuda, Hayamitsu Adachi, Shun-ichi Ohba, Hiroyuki
Inoue, Masahide Amemiya, Ihomi Usami, Chigusa Hayashi, Yoshimasa Ishizaki,
Hikaru Abe, Takumi Watanabe, Masayuki Igarashi, Daniel Ken Inaoka, Kiyoshi
Kita, Manabu Kawada, Masakatsu Shibasaki
2016 ư 10 ȸ 8 Ȧ(t\xIXɦʕ/ɦʕ)42

̓ 18 Ń ȦɀλϮîɊŹ¾ČʘϝΧΜ¾˷̍¾
MS E˓#ȢΌǑˑ˂¶ά˒˂0Ȇ̩ʳ̐
2016 ư 10 ȸ 17 Ȧ(ČʘϝŦŹþǩ̆Ź˷̍ɜ/Ɂƭ)43

̓ 64 ŃȦɀKJ^Ź¾ŹͽЋ¾Ćˈ˪-WqtgV]U.ǖΊ-ŘŔ0š˜.?BJxM[KJ^
Wq RNP Ьɪɣϗšċʭʅ˰ƥ
2016 ư 10 ȸ 23 Ȧ(ɁƭX|\`dмɁƭ)44

̓ 64 ŃȦɀKJ^Ź¾ŹͽЋ¾JxM[KJ^.B NA ϼƇú͈Ǜċš˜.Ëŷ-[ŃϣɩɣɝƱŨϤʭʅ˰ƥЬ˔˾®ʼΰ˰ĶɐеɭĊ
2016 ư 10 ȸ 23 Ȧ(ɁƭX|\`dмɁƭ)45

2nd Kumamoto IRCMS International Symposium and 17th Kumamoto AIDS
SeminarShort intracellular HIV-1 transcripts serve as biomarkers of residual immune
activation in patients on antiretroviral therapy
Aya Ishizaka, Hidenori Sato, Hitomi Nakamura, Michiko Koga, Tomohiko
Koibuchi, Ai Kawana-Tachikawa and Taketoshi Mizutani
2016 ư 10 ȸ 31 Ȧ(7;+˲ɺ«ʓЦtH/ ʼɀƦ)46

̓ 42 Ńěǘ+ħǩ0Ϛɯ\]K
Hl0eJTkŏHlěǘEŔχ+#Ĭxg̨ 3 ̧ztS
HX0ΑŴ˪Ȟħǩϭ˔̃ÎЏƆèɧKarin Weidnerʼΰ˰ĶɐƝɭĊ

37

2016 ư 11 ȸ 8 Ȧ(ВƛƦʞɼȝċ¾Цmk/Вƛ˲)47

̓ 10 ŃOkxG]˷̍¾
î΁Ϩɶ Atg8 +ȢΌ̮ħ͹˨λ Hfl1 +0˱¨Æ˓ΐɊƚƝ̑ǒ2016 ư 11 ȸ 14-15 Ȧ(NASPA nOdn/Ȣʰ)48

̓ 10 ŃOkxG]˷̍¾
Atg8-PE 0mqjI^T50åɣǩ+˱¨Æ˓ΐɊƚϞȺ2016 ư 11 ȸ 14-15 Ȧ (NASPA nOdn/Ȣʰ)49̓ 30 ŃȦɀMJ_Ź¾ŹͽЋ¾̷¾
Cell-associated HIV RNA (Short Transcripts)+ T ̪͑ʒǛċ+0ϹϘ˶ŎǈÄͷ̃ǧɅ¯͂ĠηϝŶЮʢȳǇ̏ơзơĪиǢɼΰşõ
2016 ư 11 ȸ 25 Ȧ (7˲ɺ«ʓ`d/вÜƜƦ)50

28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics
Symposium
Mechanism of action of a novel anti-tumor antibody, anti-CXADR 6G10A
Manabu Kawada, Hiroyuki Inoue, Masunori Kajikawa, Masahito Sugiura,
Shuichi Sakamoto, Sakiko Urano, Chigusa Karasawa,Ihomi Usami, Mitsuru
Futakuchi
2016 ư 11 ȸ 29 Ȧ(ICM International Congress Center Munich/Munich/Germany)

51

28th

EORTC-NCI-AACR

Molecular

Targets

andCancer

Therapeutics

Symposium
Inhibition of osteosarcoma cell growth by geraniin in vivo
Daisuke Tatsuda, Isao Momose, Shun-ichi Ohba, Yoji Umezawa, Manabu
Kawada, Masakatsu Shibasaki
2016 ư 11 ȸ 29 Ȧ(ICM International Congress Center Munich/Munich/Germany)52

̓ 39 ŃȦɀîŶˑ˂Ź¾ư¾
JxM[KJ^͆ΙЙŒ.ŷŌBî̙Ћħ\Umϧñ0ɩ͒ΐɊʭʅ˰ƥ2016 ư 11 ȸ 30 Ȧ (t\xIXɦʕмɦʕƦ)53

̓ 37 ŃȦɀ͟ƳͶˋŹ¾Źͽ̷¾Intervenolin О̻Å.?BȢΌwͮʆˣǫ˚0Ϸ˦Ŧ˶ȳś˔ǔŽϞćÚɋĐͬŦƺÎϽϥÚ©ďƟЊ̊ƛÔenMČʯɐеɭĊơ˔Ź
2016 ư 12 ȸ 2 Ȧ (̝ŶX|\`d/Яĝ˲)54

̓ 56 Ń͟ƳċŹ¾ưɪŹͽЋ¾

38

ʤύč

JxM[KJ^.B NA ϼƇú͈Ǜċš˜.Ëŷ-[ŃϣɩɣɝƱŨϤʭʅ˰ƥЬ˔˾®ʼΰ˰ĶɐеɭĊ
2016 ư 12 ȸ 3 Ȧ (7;+˲ɺ«ʓЦtH/ʼɀ)55

̓ 43 Ńȹɩáŏ×̨ċŹΓΩ¾
ȢΌ·ɕ~K̨{iˏ0ΗΒ,ħǩ,ċΑŴ50ƘϷϭ˔̃ÎĠͣÐȻ˔ƼŶɐƝɭĊʼΰ˰Ķ
2016 ư 12 ȸ 10 Ȧ (µĢƦɺ¾Ц/µĢƦ)56

The 21st JFCR-International Symposium on Cancer Chemotherapy(JFCR-ISCC)
Ertredin, a new inhibitor of sphere & tumor growth, regulates mitochondrial
respiration and glycolysis in EGFRvIII-transformed cells
Sonoko Atsumi, Chisato Nosaka, Hayamitsu Adachi, Tomoyuki Kimura,
Yoshihiko Kobayashi, Hisashi Takada, Takumi Watanabe, Shun-ichi Ohba,
Hiroyuki Inoue, Manabu Kawada, Masakatsu Shibasaki and Masabumi Shibuya
2016 ư 12 ȸ 14-15 Ȧ (Ȧɀ̆ŹȾɇЦ/Ɉ¬)57ȢŹͽЙŒ˷̍̠ƋöǏěǘŗ

̓оŃßϷ\]KzU

HRnkEɾɕ̉ùШÅ+BΑŴ˪Ȟ C–C ̮ħǆǩěǘ
ʼΰ˰Ķ2017 ư 1 ȸ 26 Ȧ (ĪĠƗŦŹ ES ̷ħЦнІ ES ~/ĪĠƗ)58ȢŹͽЙŒ˷̍Źͽ˷̍ȔȎŔˮǆǩÙ̒jĈ˂ȔȎzgkxNǩɌ˦Ϳ¾ȢΌǳ CXADR ǳÅ.?BǳFÆ˓0ΐɊơ˔Źª΃Ʊɚơˬ̤ɃʖЊ¯ŎɀÑʖϭĴŶĺʳĐͬżÄ͂½Ï͂§ğØś˔ǔ
2017 ư 2 ȸ 7 Ȧ (ˍˎʧ~i/ʬη˲)59ȦɀόͧċŹ¾ 2017 ưƷŦ¾
Lentzea ƙȖ̸ͮ˕ɇȢΌ trehalose О̻Å lentztrehalose О0ɣϗ+ˑ˂ʒǛĳ˔Îʳ̐ŦƺÎʋťϭĳɧɏϭĸ£Ï˔˕͂ŶɘČ7<ɋĐͬТƜƧȫŶʡΰÖŶơ˔Ź©ďƟЊ
2017 ư 3 ȸ 19 Ȧ (¬ϦŰŶŦŹ/¬Ϧ)60ȦɀόͧċŹ¾ 2017 ưƷŦ¾ʛʘƵʌ˕ɇȖ̸ͮ0ˑ˒BȢΌ enediyne ̣ǳˑ˂λ.ϹB˷̍©ďƟЊʳ̐ɘČ7<ɋĐͬʋťϭ ĳɧāͷĐȬ

2017 ư 3 ȸ 19 Ȧ (¬ϦŰŶŦŹ/¬Ϧ)61ȦɀόͧċŹ¾ 2017 ưƷŦ¾

39

MALDI-TOF MS E˓#Ȗ̸ͮ0έôЬɨ΃Ŷʋťϭĳɧ©ďƟЊʳ̐ɘʅʏ§āͷĐȬ

2017 ư 3 ȸ 19 Ȧ (¬ϦŰŶŦŹ/¬Ϧ)62ȦɀόͧċŹ¾ 2017 ưƷŦ¾Ȗ̸ͮ0ˑ˒BȢΌ 48 ķˏTJl0ɣϗʳ̐ɘČ7<ʋťϭĳɧɋĐͬŦƺÎ©ďƟЊ
2017 ư 3 ȸ 19 Ȧ (¬ϦŰŶŦŹ/¬Ϧ)63ȦɀͶŹ¾̓ 137 ư¾
HRHl0eJTkŏΑŴ˪ȞHlěǘ
Zijian LIU, Toshifumi TAKEUCHI, Roman Krzysztof PLUTA,
Fernando Arteaga ARTEAGA, Naoya KUMAGAI, Masakatsu SHIBASAKI2017 ư 3 ȸ 25 Ȧ (µĢŉЈ`d/Ɔő˲)64ȦɀͶŹ¾̓ 137 ư¾
Pmqfy.ňƁċ# Nd/Na ˜̉ 2 ɕϯƙΑŴ.?BЬĆˈ˪x̣nkHlěǘ0Ϸ˦ϭƚǉ®ʼΰ˰ĶɐƝɭĊ
2017 ư 3 ȸ 25 Ȧ (µĢŉЈ`d/Ɔő˲)65

ȦɀͶŹ¾̓ 137 ư¾˫ǩϵńŶĞƉÅš˜Å vIII ˦ˉ̪͑0ρŗГËŷǛśɳϼƇʒǛEȹBÂîŶċħ˂0ɣϗʒǛ˱Ϲ˷̍ȽɅȳʥ͂ŊŶĠɋͥǇϭŎĐϫƠɀ͉ŶŦƺÎơ˔ŹʲΰɭģʤύčɐеɭĊ
2017 ư 3 ȸ 25 Ȧ (µĢŉЈ`d/Ɔő˲)66

ȦɀͶŹ¾̓ 137 ư¾α-H]l-7-H[JlHlE˓#HRnkxOfVk
50eJTkŏΑŴ˪ȞHlěǘ0Ϸ˦ЏƆèɧϭ˔̃ÎWeidner KARIN, ʼΰ˰ĶɐƝɭĊ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)67

ȦɀͶŹ¾̓ 137 ư¾α-Cl Ę4 Br Hl0eJTkŏΑŴ˪Ȟ Mannich ěǘźĕPandur Venkatesan BALAJI, ʼΰ˰ĶɐƝɭĊ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)68ȦɀͶŹ¾̓ 137 ư¾
ȢΌ·ɕ~K̨{iˏEΑŴ+B˰ȇ˪Hlċěǘ0Ϸ˦ϭ˔̃Î, ĠͣÐ, Ȼ˔ƼŶ, ɐƝɭĊ, ʼΰ˰Ķ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)

40

69

ȦɀͶŹ¾̓ 137 ư¾ÚΑŴNi ΑŴ.?BMi0 α-C(sp3)-H ƀ͒Ŕċěǘ
ź¹èʼΰ˰ĶɐеɭĊ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)70

ȦɀͶŹ¾̓ 137 ư¾
Cu/Pd sJmŏΑŴE˓# α-CF3 Hl0 α-ȞHċěǘгͷΣʼΰ˰ĶɐеɭĊ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)71ȦɀͶŹ¾̓ 137 ư¾ϯƙϧÁ΢ο.?B̏ÅńŶ.οńBГƯДHl0Ȇ̩ρ̏ǥǁʼΰ˰ĶɐƝɭĊ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)72

ȦɀͶŹ¾̓ 137 ư¾
Leptolyngbyolide C 0ΑŴ˪ÞħǩƞϚʤύčɐеɭĊ
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)73

̓ 3 ŃŉЈþͶ\]KзȦɀͶŹ¾̓ 137 ư¾и
Amycolamicin, a novel antibiotic as a promising candidate for Clostridium
difficile infection: antibacterial activity, mode of action, and in vivo efficacy
Yoshimasa Ishizaki, Kazushige Sasaki, Hideki Hashizume, Chigusa Hayashi,
Kunio Inoue, Hayamitsu Adachi, Yoshiaki Takahashi, Masayuki Igarashi,
Yoshio Nishimura, Yuzuru Akamatsu, Akio Nomoto, Masakatsu Shibasaki
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)74

̓ 3 ŃŉЈþͶ\]KзȦɀͶŹ¾̓ 137 ư¾и
Anti-Helicobacter pylori activity of a novel derivative of intervenolin
Tomokazu Ohishi, Tohru Masuda, Hikaru Abe, Chigusa Hayashi,
Hayamitsu Adachi, Shun-ichi Ohba, Masayuki Igarashi,
Takumi Watanabe, Daniel Ken Inaoka, Kiyoshi Kita,
Masakatsu Shibasaki, Manabu Kawada
2017 ư 3 ȸ 26 Ȧ (µĢŉЈ`d/Ɔő˲)75

ȦɀͶŹ¾̓ 137 ư¾
In(OTf)3-BHA ΑŴE˓#nk0 α,β Уĳ 7-H[JlHl50
MRbϡǵ˪Ȟ 1,3-ĚɡŶ´āˏċěǘǃȬʼΰ˰ĶɐеɭĊ
2017 ư 3 ȸ 27 Ȧ (µĢŉЈ`d/Ɔő˲)76

ȦɀͶŹ¾̓ 137 ư¾41Ú˜Ǜċ+˃˜˪ɼ̨̮ħ.?B̏Åϡǵ˪ġϓxNjIU
Chris OPIE, ʼΰ˰ĶɐƝɭĊ
2017 ư 3 ȸ 27 Ȧ (µĢŉЈ`d/Ɔő˲)77ȦɀͶŹ¾̓ 137 ư¾
F-ϸλ˱¨Æ˓.Õŧʻ˂ Leucinostatin A 0ΑŴ˪ȞÞħǩ˷̍ϽϥÚŦã¯Ǘơ˔ŹʤύčɐеɭĊ
2017 ư 3 ȸ 27 Ȧ (µĢŉЈ`d/Ɔő˲)78

ȦɀͶŹ¾̓ 137 ư¾
t]KΑŴ.?Bʸ̨- ɼ̨̮ħʒǛċEõ˓#ǳ HIV úHsPv0ħǩϹʜЬɨͥȯɐеɭĊ
2017 ư 3 ȸ 27 Ȧ (µĢŉЈ`d/Ɔő˲)зси˃ôΫ̈́1ȦɀŦŹŦŹЀ ˑ˂θʪ̆Ź˷̍̆Ǒˑ˂ċŹ˷̍ǭ.Bǳˑ˂λ0Ȇ̩+Ϸ˦ǳ̮ɕͮÆ˓EȹBċħ˂ CPZEN-45 EÉ.
˶Ɲ¯ƒ

2

ČϫŦŹͶŹϥŦŹЀΫ̈́þͶŔ˼˷̍0¥ȼ/ƘϷF˷͇̍0ǳFͶ@0ǣɏˡͶơ˔Ź2016 ư 12 ȸ 8 Ȧ (ČϫŦŹͶŹϥ 1 ĥЦ/Ɉ¬)зтиn^^1

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾.)ʥ͂ŊŶ̧˷̍ķз̓ 1 ˑ˂ʒǛ˷̍ϥиErtredin ΢ƓÅ.?B EGFRvIII ˦ˉ̪͑0 3D-sphere ǆǩϼƇ+͚ˢǆǩ

*^dιEĞι

2016 ư 6 ȸ 2 Ȧ2

̓20ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾.)Ŧ˶ȳ˷̍ķзʇʑȔǭизADP-\иċϨ̨dRaEɥ˪+#Fʆˣʊ0Ϸ˦*˷̍ůĄιEĞι
2016ư6ȸ2Ȧ
3

ϡǵ˪OkxG]ɥ˪0#F3λêЋÅEΡέЇЍBPn_EΐȬϭ˔ƘˑîŶɣϗΐɊϥƪ˷̍ķ
2016ư6ȸ17Ȧ

4

OkxG]ŲĈ΂̀0ɣ̛Pn_EΐȬ

42ϭ˔ƘˑîŶɣϗΐɊϥƪ˷̍ķ
2016ư7ȸ12Ȧ
5

̓37ŃȦɀ͟ƳͶˋŹ¾Źͽ̷¾.)Ŧ˶ȳ˷̍ķзʇʑȔǭиIntervenolinО̻Å.?BȢΌwͮʆˣǫ˚0Ϸ˦*Ö̃ʮЛι0ιEĞι2016ư12ȸ5Ȧ
6

̓29ŃȹɩħǩċŹē¾˷̍¼˗ι.)ϭ˔̃Î˷̍ķзȹɩħǩ˷̍ϥиÙШ˪îŶΡέΑŴ0̠ƋΗΒ.Ŕ(Hl̮ħïȡěǘ0Ϸ˦ ADEKA ˷̍¼˗ιEĞι
2016ư12ȸ15Ȧ

7ȢЬʒǛHl̮ħǆǩΑŴEϷ˦ȹɩħǩ˷̍ϥ2017ư1ȸ31ȦзуиȢ͊Ŗϝ̔
1

T_Hgz ǟʽƃƹ
кȢ#-FʆˣʊϷ˦5кƌŞn^
ʇʑȔǭ Ŧ˶ȳ˷̍ķ
2016 ư 6 ȸ 22 Ȧ2̪͑0åõ˓OkxG] Ĉì0²̬8ΐȬȻȦȢ͊ DIGITALîŶɣϗ ϭ˔Ƙˑƪ˷̍ķ
2016 ư 7 ȸ 12 Ȧ

3

˴EǸ
кĎͶĵĆˈ˪.ħǩкȦ̭˒ɠȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 7 ȸ 25 Ȧ4

q|ι °ư1,-BċŹȹɩħǩěǘ

ȹÿȻȦȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 9 ȸ 22 Ȧ5

q|ι¥ǠɷȦȢ͊ ţð43ɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 1 Ȧ6q|ι °ư;ʽйċŹιΤŠȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ7Ȧɀ®ȹÿÒ΄.ʍ˯ q|ι@˦Ϳ

¢Ɇ0¾΀ʾ͇@;ΏłŉȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ8Ȧɀ® 3 ưϘ̴-Bмq|ι@˦Ϳм͠ʻ̆ŹпιмĨϭɹзȨċǩПļи@ȼǌмfKJOАʂϷ˦мċŹιмƯĳιм¢Ɇ0¾;Ò΄мȝŹι̭ʠŹιмɅɹ1 ˛®ɻмȝŹιƆƝȦȦȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ
9q|ιмȦɀ® °ư;ʍ˯м@˦Ϳ3 ưϘ̴.ȼǌм΀ʾ͇¢Ɇ0¾;Ò΄ˌˊȢŖ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ
10Ʌɹ °ư;ȝŹιÒ΄ q|ι@˦Ϳм͠ʻ̆Ź 3 ιϘ̴Ğι.ȼǌ
ʄ̼dJ^ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ11q|ι3 Ȧ@˦Ϳ Ʌȭɧɹ2016 ư;ȹÿÒ΄ʼɀȦȦȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ12Ȧɀ®Ğι °ư;ʍ˯ q|ιΉȦɀȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ

44

@˦Ϳ

13

q|ι@˦Ϳ Ȧɀ® °ư;ȼǌ ȝŹι ɅȭɧɹȹÿǢŵȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ14

@˦Ϳ ͠ʻ̆Ź 3 ưϘ̴-BȦɀ® °ư;ɒçч q|ιĦιŉȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ15Ȧɀ®Ϙ̴ɒç.ʍ˯ q|ι@˦Ϳ ɀƻɅɹ@ȼǌ¬ϦȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ16Ȧɀ®Ğι °ư;ч ͠ʻ̆Ź 3 ưϘ̴.ȼǌɀƻɹз˲ß̏ŦŹʊ®ˋ¦ϵи;Ò΄к@q|ι˦ͿВƛȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ17

3 Ȧ@˦Ϳ °ư0q|ιмȦɀ®Ğι.ȼǌBм͠ʻ̆Ź3 ưϘ̴ȝŹƯĳ.;ʍ˯ϭȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ18

q|Ħι@˦Ϳ Ȧɀ®Ğι °ư;ȼǌɅȭɧɹ<ƯĳŅÅʍ˯ɈŮȦŖ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ19q|ι

 3 Ȧ@˦Ϳ Ȧɀ®Ğι°ư;ʍ˯ ͠ʻ̆Ź

3 ưϘ̴.ȼǌ ȝŹɅȭɧɹȹÿ̅˔ЭȢŖ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 2 Ȧ20

q|ι>@˦ͿÄηȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ

45

21

q|ι¥Ǡ˒̭Ȣ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ22

q|ιĦι>@˦Ϳ^dk ϬÿʋòΎʦ;ȹÿȦɀƣɠȢ͊ȢɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ23

5 Ȧ.q|ċŹι˦ͿȦɀǎǡ0ȹɩċŹ*Ğιȼǌ
ZVJ^hɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ24

q|Ħι.ȹÿȦɀ®Ò΄Ȧð^hȢ͊ɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ25

16 q|ι>@Ħι˦Ϳ ͠ʻ̆ŹȦɀ® 3 ưϘ̴ȼǌƯĳ¢Ɇ0¾-,.ʍ˯
ÐʴɷȦȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ

26

°ϙ0ʺʹ

q|ι,-B Ȧɀ® 3 ưϘ̴-B˒̭Ȣ͊ ȻðɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ27ɈƣŦ0ŦЅɒΟșȃq|ĎŹˑˋŹιEĞιȦɀ® 3 ưϘ̴ 25 ®˯Ŗ˴Ȣ͊ɐеɭĊ˷̍ǭǭϵ2016 ư 10 ȸ 3 Ȧ28

Ϊ.ǿ8̴BŦЅF++;.
кϝã=A0͠РÆ˓˷͇̍кČʘϝȢ͊ ţðîŶɣϗ ϭ˔Ƙˑƪ˷̍ķ
2016 ư 10 ȸ 7 Ȧ
29

ċŹħǩ.ȢΑŴ

46

кƽɛ˂øʣ0ġ͒Ǜ―ɷȦȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2017 ư 1 ȸ 31 Ȧ
30Hl̮ħ'BΑŴкǑˑ˂ċŹ˷ƽɛ˂ì―Ȧ̭˒ɠȢ͊ ȻðɐеɭĊ˷̍ǭǭϵ2017 ư 1 ȸ 31 Ȧ

31˷̍ƅ0~zкϟîϭ@0φ͋1ȷǍ0ǿǫ*;

A7#к

Cosmo Bio News No.127îŶɣϗ ƚƝ̑ǒ˷̍ķ
2017 ư 2 ȸ 14 ȦзфиĞι
1

Ưǩ 27 ưƷ ȦɀFîŶɥ˪ʆˣŹ¾ ˷̍ůĄι(ADP-\)ċϨ̨dRaEɥ˪+#Fʆˣʊ0Ϸ˦Ŧ˶ȳ ʇʑȔǭ˷̍ķ

2

̓ 20 ŃȦɀFîŶɥ˪ʆˣŹ¾ŹͽЋ¾ ^dιEntredin ΢ƓÅ.?B EGFRvIII ˦ˉ̪͑0 3D-sphere ǆǩϼƇ+͚ˢǆǩǱöʥ͂ŊŶ ̓ 1 ˑ˂ʒǛ˷̍ϥ̧˷̍ķ3

̓ 29 ŃȹɩħǩċŹē¾˷̍¼˗ι ADEKA ˷̍¼˗ιÙШ˪îŶΡέΑŴ0̠ƋΗΒ.Ŕ(Hl̮ħïȡěǘ0Ϸ˦ϭ˔̃Î ȹɩħǩ˷̍ϥ˃ô˷̍ķ

47